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 Gene therapy requires efficient delivery and expression of genes in 
specific target cells, but most current gene therapy vectors fail to accomplish this.  
The goal of these experiments was development of a gene therapy system for 
breast cancer.  The combination of viral and bacterial vectors would create one 
gene therapy system that achieves these goals and consists of (i) highly infectious, 
attenuated bacteria containing a retroviral vector that would be efficiently 
delivered to lymphoid cells in the gut and (ii) a mouse mammary tumor virus 
(MMTV)-based vector capable of trafficking from lymphocytes to mammary 
epithelial cells where target gene expression can occur. 
 In initial studies, development of a bacterial delivery system that traffics 
through M cells and targets lymphocytes was attempted using Shigella, Yersinia, 
and Escherichia coli.  A Shigella asd mutant was unable to efficiently deliver 
genes to lymphocytes, while gene delivery by the Yersinia type III secretion 
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system caused toxicity to eukaryotic cells.  E. coli expressing invasin, which 
binds β1 integrins on lymphocytes, was still unable to specifically target 
lymphoid cells. 
 In attempts to develop a retroviral gene therapy vector, an MMTV hybrid 
provirus was tagged with a green fluorescent protein (GFP) to follow MMTV 
trafficking in the mouse.  However, GFP insertion into the provirus disrupted 
either cis- or trans-acting elements necessary for replication.  To facilitate the 
mapping of these elements in the MMTV genome, transposon-based mutagenesis 
was performed, and three MMTV mutants were identified with insertions in the 
env gene.  These mutants had defective cytoplasmic export of unspliced gag 
mRNA and, thus, were unable to synthesize Gag.  In coinfection experiments with 
MMTV env mutants, wild-type MMTV complemented the defect in unspliced 
mRNA export.  A novel, doubly spliced, mRNA was identified from MMTV-
infected cells, and predicted protein motifs showed similarities to other retroviral 
trans-acting proteins involved in unspliced mRNA export.  These results 
suggested that MMTV expresses a trans-acting protein that allows nuclear export 
of intron-containing RNA and should be reclassified as a complex retrovirus. 
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 Gene therapy is the delivery of functional genes to treat inherited or 
acquired diseases.  Diseases ranging from genetic disorders to various types of 
cancer could potentially be treated through the use of gene therapy (96,116).  A 
major difficulty for successful gene therapy treatment is the development of a 
gene delivery system to target specific cells.  An optimum delivery system, or 
vector, first requires efficient gene transfer.  Other factors important for gene 
therapy include cell or tissue-specific delivery, facile vector construction 
amenable to large genes, cost-effective delivery, and importantly, vector safety.  
All these factors are unlikely to be incorporated into one vector and, therefore, 
several different vectors (each having their own advantages and disadvantages) 
have been developed.  The main vectors used today in gene therapy are viral 
vectors (adenoviral and retroviral vectors, most commonly) and non-viral vectors 







1.1.2 Non-viral vectors  
 
 
 Non-viral gene therapy involves the direct transfer of DNA to a cell either 
through direct DNA injection or uptake of DNA through a chemical complex 
(122,249).  The two most common methods of injection include the injection of 
purified DNA, usually directly into tissue or through systemic injection, and the 
use of a gene gun, which calls for microscopic gold beads to be complexed with 
the DNA and injected into cells with a helium gun (159,189).  The chemical 
complexes for non-viral gene therapy consist of liposomes and polymers.  The 
liposomes are usually cationic lipids that form a bilayer around the DNA and then 
are able to associate with the plasma membrane of the cell to allow the nucleic 
acid to be delivered by membrane fusion or endocytosis (209).  The polymers 
consist of DNA conjugated to polycations, such as polylysine or 
polyethylenimines, which also allow the DNA to be delivered to cells (127,189).  
These vectors all have the advantages of: (i) simplicity to use, (ii) low cost 
production, and (iii) most importantly, safety since no signs of toxicity have been 
reported and an immune response against the DNA has not been shown.  
However, gene delivery is inefficient using these vectors, and the DNA delivered 
does not integrate into the host cell genome.  Therefore, expression of the gene is 
transient.  Due to the inefficiency and short duration of gene expression, these 
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vectors are now being utilized as DNA vaccines until improvements can be 
developed (122,127,159). 
 
1.1.3 Adenoviral vectors  
 
 
 Some viruses are considered suitable for gene therapy vectors since they 
have evolved to deliver their genomes to target cells.  Adenoviruses are double-
stranded linear DNA viruses that are approximately 36 kilobases (kb) in length 
and are currently being used as vectors in gene therapy.  These vectors are highly 
suitable for gene delivery since they:  (i) are able to incorporate ca. 38 kb of 
foreign DNA, (ii) infect both non-dividing and dividing cells, (iii) have a very 
broad host range, (iv) can be produced to high titers, and (v) have high levels of 
expression of the delivered gene (13,209,249).  Many generations of adenoviral 
vectors have been developed with the first and second generations replacing 
different genes, which are either not necessary for viral replication or are provided 
by complementation in the producer cell lines.  However, one problem is the 
appearance of replication-competent adenovirus through homologous 
recombination events with the viral sequences from the producer cell lines.  
Furthermore, adenovirus is capable of eliciting an immune response.  Thus, the 
immune system removes cells that express the therapeutic gene together with any 
viral proteins, leading to transient gene expression (116,170). 
 4 
 To eliminate the replication-competent adenovirus and the immune 
response, an adenoviral vector lacking most of the viral genes was developed.  
These gutless vectors use the Cre/loxP system to delete 25 kb of the adenoviral 
genome, leaving only the inverted terminal repeats and the packaging signal, and 
allowing the incorporation of large genes of up to 32 kb.  These vectors also 
require a helper virus that encodes proteins needed for replication and is deleted 
of its packaging signal to avoid contamination of the vector with replication-
competent adenovirus (116,240). 
 The new adenoviral vectors produced today show great promise for gene 
therapy, but there are still disadvantages.  The gutless vectors reduce the immune 
response, but the viral capsid still produces an immune response that makes it 
difficult to use the adenoviral vectors for repeated use.  Finally, although a broad 
host range is advantageous for the vectors, the ability to infect most epithelium-
derived cell types does not allow for control of gene delivery when using systemic 
methods of introduction (13,212,240,259). 
 
1.1.4 Retroviral vectors  
 
 
 Retroviruses are another group of viruses that are presently being used in 
gene therapy.  These enveloped viruses contain two copies of single-stranded 
RNA that are copied into a DNA intermediate that then can be stably integrated 
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into the host cell genome.  These vectors have the following advantages:  (i) ease 
of manipulation, (ii) ability to accommodate large genes, (iii) infection of a broad 
range of target cells, and (iv) the ability to integrate into the host cell genome, 
allowing for stable expression over long periods (114,116,170). 
 Retroviral vectors have been developed using both simple and complex 
retroviruses, most commonly, the murine leukemia virus (MLV)- and the human 
immunodeficiency virus type 1 (HIV-1)-based vectors, respectively.  Both types 
of retroviral vectors delete most or all of their coding regions, leaving only the 
cis-acting elements required for RNA packaging (96,116).  These vectors are 
unable to produce a viral particle and, therefore, cell lines or co-transfected 
plasmids providing the viral proteins in trans are required.  The first generation of 
helper cell lines expressed all viral proteins from one construct that lacked a 
packaging signal.  However, recombination between the helper and the gene 
vector could restore the packaging signal to the helper, and replication-competent 
viruses then would be produced.  Current cell lines express viral proteins from 
two different constructs, a gag-pol construct and an env construct, that lack 
significant sequence homology with each other or the RNA to be packaged 
(114,165).  These cell lines also allow pseudotyping of the vector with different 
envelope (Env) proteins since Env is expressed from only one construct and is not 
necessary for recognizing and packaging the RNA.  The most common Env 
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protein used is the vesicular stomatitis virus G protein, which allows a broad host 
range for infection as well as production of higher virus titers (96,170). 
 As with adenoviral vectors, the retroviral vectors also have disadvantages.  
The MLV-based vectors, classified as simple retroviral vectors, are unable to 
infect non-dividing cells, which reduces the cell types targeted for gene therapy.  
However, this problem can be overcome by the use of the HIV-based vectors, or 
complex retroviral vectors, which are capable of infecting non-dividing cells.  In 
addition, the titers generated using retroviral vectors are low when compared to 
the titers generated with DNA virus vectors (114,189).  The possibility of 
producing replication-competent viruses through recombination events also is a 
major concern, although many of the current retroviral vectors have been 
modified to reduce the amount of sequence homology between all vectors.  
Finally, the integration of these retroviral vectors is a random event which can not 
be controlled, and insertions might inactivate important genes or unintentionally 
activate cellular oncogenes (96,114,249).  Recent examples of leukemia induction 
after high titer retroviral therapy have been observed (37,80). 
 
1.1.5 Bacterial delivery systems  
 
 
 Gene therapy requires a delivery system that is capable of targeting 
specific cells without eliciting an immune response or resulting in a pathogenic 
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virus by recombination.  Many of the current viral vectors do not fulfill at least 
one of these requirements.  An alternative to the viral vectors is bacteria-mediated 
gene transfer.  Bacterial delivery has the advantages of tissue tropism as well as a 
cell-to-cell spread mechanism that might allow bacteria to target underlying tissue 
layers that are not infected by viral vectors.  Bacterial plasmids also are able to 
accommodate large amounts of coding sequence.  Therefore, bacterial vectors 
lack the size restriction that is necessary for the packaged viral vectors.  An 
immune response can be avoided if the bacteria are cleared from the body soon 
after infection occurs, either through the use of antibiotics or self-destruct features 
built into the vector (149,246). 
 Bacterial delivery systems are still being developed, yet they all share the 
same basic concept of plasmid delivery.  Attenuated bacteria carrying the plasmid 
to be delivered invade target cells through their usual route of entry, usually 
phagocytosis.  Once inside the cells, the bacteria are released from the phagocytic 
vacuole into the cytoplasm, where they undergo lysis as a result of antibiotic 
treatment, an inducible autolytic mechanism, or by engineering bacteria that 
require essential components that can not be provided by the target cells (43).  
Lysis of the bacteria allows the release of the plasmid into the cytoplasm of the 
target cells, where it can be transported to the nucleus and subsequently be 
expressed.  Such delivery systems are being developed in Salmonella 
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typhimurium and Salmonella typhi, Shigella flexneri, Listeria monocytogenes, and 
recombinant Escherichia coli (245,246). 
 






 Shigella is a gram-negative bacterium that causes shigellosis or bacillary 
dysentery in humans (158,223).  Only 10 to 100 bacteria are needed for an 
infection, which can vary from mild diarrhea to a severe form that includes an 
acute inflammation reaction leading to colonization and destruction of the colonic 
mucosa.  Shigella is transmitted from person-to-person contact or contaminated 
foods, and then passes through the stomach until it reaches the intestine (199). 
 The lining of the intestine is made up of epithelial cells that are tightly 
joined and form a barrier to prevent infection by microorganisms.  Therefore, 
Shigella and other pathogens must find an alternative way of infecting the 
epithelium (200).  Within the intestine, Shigella interacts with membranous 
epithelial cells (M cells), which are specialized cells in the follicular associated 
epithelium that overlay lymphoid follicles such as solitary nodules and Peyer’s 
patches (Fig. 1.1).  The M cells take up the Shigella into vacuoles through a 
‘ruffling process’ similar to that observed with epithelial cells.  However, the 








Fig. 1.1. Shigella invasion of epithelial cells. 
 
Shigella crosses the epithelial barrier by translocation through M cells 
and subsequently infects macrophages.  The infected macrophages 
undergo apoptosis which releases the bacteria and initiates 
inflammation with the release of IL-1β .  Polymorphonuclear leukocyte 
migration to the inflammation causes destabilization of the epithelium 
and allows Shigella to invade epithelial cells through the basolateral 
surface.  [Adapted from Sansonetti and Phalipon, 1999 (201)]. 
 
 10 
and delivered to the lymphoid follicles.  Shigella then infects macrophages, which 
undergo apoptosis and release interleukin-1β, eventually leading to an 
inflammatory response.  The inflammation attracts polymorphonuclear leukocytes 
(PMNs), disrupting the epithelium and allowing Shigella to infect these cells 
through their basolateral pole (198,200,201,242). 
 Shigella also interacts with typical epithelial cells and induces cytoskeletal 
rearrangements that allow the bacterium to be taken up through membrane 
ruffling and macropinocytosis into a vacuole.  In epithelial cells, Shigellae lyse 
the vacuole, escape into the cytoplasm, and replicate.  Shigellae move inside the 
cell as well as from cell to cell through actin polymerization at one pole of the 
bacterium, leading to further colonization of the epithelium (158,199,223). 
 S. flexneri is presently being studied as a bacterial delivery system since it 
is capable of cytoplasmic entry via vacuole lysis.  To deliver plasmid DNA, 
several attenuated mutants have been developed (245,246).  Such mutants include 
ones with an inability to synthesize aromatic amino acids (aroA) (161), deficiency 
in guanine nucleotide production (guaBA) (160), and defects in cell wall synthesis 
(asd, dapB) (43,207).  Since the eukaryotic host cells are unable to provide the 
components necessary for propagation of these bacteria mutants, the bacterium 






 Yersinia is a gram-negative coccobacillus that is usually spread through 
contaminated food or water.  There are three species of Yersinia:  Yersinia pestis 
and Yersinia pseudotuberculosis, which are primarily pathogens of rodents, and 
Yersinia enterocolitica, which is a human pathogen.  Y. pestis causes the plague 
while Y. pseudotuberculosis causes mesenteric adenitis and septicemia; however, 
Y. enterocolitica is able to cause a variety of infections ranging from mild 
diarrhea to mesenteric lymphadenitis.  Although the three Yersinia species are 
pathogens of different hosts and cause different diseases, all use the same route of 
infection (21,42,99). 
 Yersinia survives at cooler temperatures and the bacterium is found in 
contaminated food and water in the environment, but it also must replicate once it 
infects a host with a higher temperature.  Yersinia contains several pathways for 
host cell attachment, which are all dependent on regulation by temperature 
(16,99).  One pathway uses the inv gene that encodes the protein invasin and is 
highly expressed at temperatures around 25oC.  Upon entering a human host, 
which raises the temperature to 37oC, invasin expression is reduced, but still 
detectable.  The other two pathways function through the chromosomally- located 
ail gene or the plasmid-encoded yadA gene, which are both up-regulated at 37oC 
(21,99).  Invasin allows Yersinia to initiate an infection by targeting β1 integrins 
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on M cells, resulting in invasion and translocation to the lymphoid follicles, or 
Peyer’s patches (Fig. 1.2) (201).  Subsequently, invasin is down-regulated, and 
the ail gene is up-regulated, allowing Yersinia to bind, but not invade, host cells.  
Yersinia then is able to replicate extracellularly and to exert effects on host cells 
to evade the immune system, thus causing a systemic infection.  YadA assists 
Yersinia targeting of M cells as well as binding to the mucus layer, which 
overlays the mucosal epithelial cells, and the intestinal brush border membranes.  
These functions allow colonization of the intestinal tract (21,139). 
 Yersinia protects itself from the host immune system through the type III 
secretion system (TTSS) (41,124).  Yersinia binds to macrophages and secretes 
proteins that:  (i) impair phagocytosis, (ii) inhibit the respiratory burst, (iii) trigger 
apoptosis, and (iv) suppress the release of tumor necrosis factor α.  Yersinia also 
binds to PMNs and secretes proteins that cause resistance to phagocytosis and 
inhibition of their oxidative burst.  These effects prevent Yersinia ingestion and 
killing by the phagocytes and promote phagocyte killing, thereby inhibiting a 
specific immune response (42,66).  The bacteria then can bind to other migrating 










Fig. 1.2. Yersinia invasion through the epithelium. 
 
Yersinia crosses the epithelial barrier by translocation through M cells.  
Yersinia begins to replicate extracellularly and evades the immune 
system by attaching to macrophages and injecting bacterial proteins 
into their cytoplasm.  These proteins prevent phagocytosis or the 
release of TNFα in addition to inducing macrophage apoptosis.  
Extracellular Yersinia bound to macrophages and other migrating cells 
then are able to cause local and systemic infections.  [Adapted from 





 Secretion of Yersinia effector proteins into the cytoplasm of host cells was 
shown through the use of a reporter enzyme.  Adenylate cyclase requires 
calmodulin for the production of cAMP, and calmodulin is found in eukaryotic 
cells, not bacteria.  The catalytic domain of adenylate cyclase was fused to the N-
terminal secretion and translocation domains of Yersinia outer membrane protein 
E (YopE), and Yersinia expressing this fusion protein were incubated with 
eukaryotic cells.  Increase in cAMP levels indicated that translocation of the 
YopE-adenylate cyclase fusion protein had occurred from Yersinia to the 
eukaryotic cell, which contains calmodulin required by the adenylate cyclase to 
produce cAMP (210,211).  These data suggest that the type III secretion system of 
Yersinia could potentially be used in gene therapy by fusing the secretion and 
translocation domains of YopE with a DNA-binding protein for subsequent 
transportation of a plasmid into a eukaryotic cell. 
 
1.2.3 Escherichia coli 
 
 
 Escherichia coli is a gram-negative bacillus that includes both 
nonpathogenic and pathogenic strains.  Most E. coli strains are nonpathogenic and 
are found as members of the normal intestinal flora of mammals.  The related 
pathogenic strains of E. coli contain virulence factors, which allow them to cause 
a range of diseases including diarrhea, neonatal septicemia and meningitis, and 
 15 
urinary tract infections.  Pathogenic strains are usually ingested through 
contaminated food and include enterotoxigenic E. coli, enteropathogenic E. coli, 
enterohemorrhagic E. coli, and enteroinvasive E. coli (23,85,179). 
 E. coli differs from both Shigella and Yersinia since it targets and 
colonizes the intestinal epithelium instead of being translocated through the M 
cells.  However, M cells constantly translocate antigens for presentation to cells of 
the immune system, and bacteria and viruses have targeted M cells to allow 
translocation to the Peyer’s patches for subsequent proliferation in the 
subepithelial space (201).  Benign E. coli strains, such as the laboratory strains K-
12 or DH5α, are unable to attach to the intestinal epithelium, but might be 
developed as gene therapy vectors that are sampled by the M cells and 
translocated into Peyer’s patches.  The E. coli vectors also might be combined 
with other bacterial gene therapy methods, such as the TTSS, for delivery of 
proteins and DNA or expression of a bacterial protein for specific cell targeting. 
 
1.3 MOUSE MAMMARY TUMOR VIRUS AS A POTENTIAL GENE 






 Mouse mammary tumor virus (MMTV) was first identified in 1933 by the 
Jackson Memorial Laboratory as an extra-chromosomal influence that increased 
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the incidence of spontaneous mammary tumors (106).  Mammary tumors were 
shown to occur only in females and affected multiple generations.  Bittner later 
demonstrated that an active “influence” in the milk was responsible for the high 
incidence of mammary tumors.  This active influence was first identified as a B-
type viral particle and later renamed MMTV (14,15). 
 
1.3.2 MMTV classification 
 
 
 MMTV is classified as a member of the Retroviridae family.  This family 
is further divided into seven genera based on sequence homology of the reverse 
transcriptase and according to the International Committee on Taxonomy of 
Viruses (178).  These genera are the alpharetroviruses (e.g., avian leukosis virus), 
betaretroviruses (e.g., MMTV), gammaretroviruses (e.g., murine leukemia virus), 
deltaretroviruses (e.g., bovine leukemia virus), epsilonretroviruses (e.g., walleye 
dermal sarcoma virus), lentivirus (e.g., HIV-1), and spumavirus (e.g., human 
spumavirus).  The betaretrovirus genus also contains the human endogenous 
retroviruses (HERVs) (235) and Jaagsiekte sheep retrovirus (129) in addition to 
MMTV. 
 MMTV also can be classified by route of transmission.  Endogenous 
MMTVs are located in the germline of inbred mouse strains and are transmitted 
vertically from parent to offspring as part of the mouse genome (70,254).  At least 
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45 endogenous MMTVs have been identified, but most are incapable of viral 
particle production (12).  Exogenous MMTVs found in lactating mammary glands 
are passed from parent to offspring through the milk and induce mammary 
adenocarcinomas (72).  Endogenous MMTVs are referred to by the nomenclature 
Mtv followed by a number (e.g., Mtv-1), while exogenous MMTVs are referred to 
by the nomenclature MMTV and the strain of mouse in which it was identified 
(e.g., MMTV(C3H) or C3H MMTV). 
 
1.3.3 MMTV genome organization 
 
 1.3.3.1 Virion structure  
 
 
 The MMTV virion, or infectious particle, is ca. 80 to 100 nm in diameter 
and is distinguished from other retroviral virions by a condensed, eccentrically 
placed, core (31).  The core of the virion contains the MMTV genomic RNA 
associated with several proteins and surrounded by three polypeptides.  The core 
is enveloped and contains the viral glycoproteins observed as surface spikes.  The 
MMTV virion first assembles as an immature core in the cytoplasm of the host 
cell, sometimes called intracytoplasmic A particles, and then the assembled core 
is directed to the plasma membrane for envelopment, release, and maturation 
(145).  The mature, released virion protects the MMTV genome until the particle  
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encounters and attaches to a susceptible host cell for genome delivery and 
replication. 
 The genomic RNA is encapsidated by the nucleocapsid protein (NC) and 
is associated with the reverse transcriptase (RT) and the integrase (IN) proteins 
(Fig. 1.3).  These proteins, along with the RNA, are surrounded by the capsid 
protein (CA), which makes up the core of the virion.  The protease (PR) and 
matrix (MA) proteins are located outside of the core, and the MA protein is 
associated with a modified lipid bilayer derived from the host cell.  The lipid 
bilayer contains two viral proteins, the transmembrane (TM) and surface (SU) 
proteins, which are linked together by disulfide bonds. 
 
 1.3.3.2 MMTV genome 
 
 MMTV consists of two identical, positive sense, single-stranded RNA 
molecules that are associated at their 5’ ends (49).  Each RNA genome of ca. 8.6 
kb resembles cellular mRNA due to capping at the 5’end and polyadenylation of 
about 200 residues at the 3’ end.  The addition of both modifications is performed 
by the host cellular machinery, and the cap is added co-transcriptionally while the 
poly(A) sequence is added post-transcriptionally (203).  Other small RNA 
molecules also are associated with the MMTV genome and can include ribosomal 







Fig. 1.3. MMTV virion structure. 
   
The genomic RNA is encapsidated by the nucleocapsid (NC) protein 
and associated with reverse transcriptase (RT) and integrase (IN) 
proteins.  The capsid (CA) protein surrounds the genomic RNA and 
associated proteins.  The protease (PR) and matrix (MA) proteins are 
located outside the CA core, and the MA protein is associated with the 
lipid bilayer.  The surface (SU) and transmembrane (TM) proteins are 




tRNA that is associated with a sequence near the 5’ end of the genome, which is 
the tRNALys3 for the MMTV genome.  This lysine tRNA serves as the primer for 
minus-strand DNA synthesis during reverse transcription (144).  The MMTV 
RNA genome is copied into a double-stranded DNA intermediate called the 
provirus.  The provirus includes the MMTV genes flanked by two long terminal 
repeats (LTR) that are identical sequences and comprised of the U3, R, and U5 
regions.  Integration of the provirus yields a template for transcription of viral 
RNA by RNA polymerase II (148,233). 
 The MMTV genome consists of both non-coding and coding regions.  The 
general organization of the non-coding sequences from the 5’ end of the genome 
is R, U5, primer binding site (PB), coding region, polypurine tract (PPT), U3, and 
R (see Fig. 1.4).  The R region that flanks the MMTV genome is only ca. 10 base 
pairs in length and is the smallest R region found in retroviruses (115,237).  These 
sequences allow the transfer of nascent DNA from one end of the genome to the 
other during reverse transcription.  The U5 region contains unique sequences at 
the 5’ end of the genome that directly precede the PB and becomes the 3’ end of 
the LTR.  The PB contains 18 nucleotides that bind to the tRNALys used for 
synthesis of minus-strand DNA (169).  The PPT of the MMTV genome contains 
19 A or G residues directly preceding the U3, which are not digested by RNase H 
during synthesis of the minus DNA strand, and are subsequently used as a primer 
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for the synthesis of the plus DNA strand  (136,183).  The final non-coding 
sequence of the MMTV genome is the U3 region, which contains an open reading 
frame (ORF) that encodes the protein Superantigen (Sag) not observed in other 
retroviruses.  This region also encodes transcriptional regulatory signals (54). 
 The MMTV coding region closely resembles that of other retroviruses 
with the exception of the sag gene located in the U3 region.  MMTV does not 
encode an oncogene like other acutely tumor-forming retroviruses and also has a 
longer average latency of 6 to 9 months.  Therefore, MMTV is known as a non-
acute, oncogenic retrovirus (72).  The positions of the ORFs beginning at the 5’ 
end of the genome are gag, pro, pol, env, and sag (see Fig. 1.5).  The gag gene is 
translated from the full- length MMTV genome to produce the 77 kD Gag 
precursor, which is then cleaved to produce the MA, CA, and NC proteins.  The 
pro and pol regions encode two polypeptides translated by ribosomal 
frameshifting from the full- length genome.  For the pro region, a -1 frameshift is 
used to extend past the Gag precursor to produce a 110 kD polypeptide from 
which the PR protein is cleaved in cis.  Two -1 frameshifts are used to produce a 
160 kD polypeptide that encodes the RT and IN proteins (105).  The env gene is 
translated from a singly spliced transcript that is initiated from a U3 promoter to 
produce the Env precursor polypeptide.  This precursor is cleaved into two 
glycoproteins, the TM and SU proteins (92)  The env gene also contains an 
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internal promoter used to initiate transcription of singly spliced sag mRNA, which 
then is translated into the Sag protein (155). 
 
1.3.4 MMTV proteins  
 
 
 1.3.4.1 Proteins expressed from the gag gene  
 
 
 The gag gene is translated from the full- length MMTV genome to produce 
the three major proteins MA, CA, and NC, which represent the internal structural 
proteins of the virion.  These proteins are found in the immature virion as the Gag 
precursor polypeptide, and cleavage into the  final protein products does not occur 
until during or immediately after budding.  Since the virion is assembled from the 
precursor polypeptide, the virions contain an equal number of the mature proteins 
MA, CA, and NC after cleavage of the precursor polypeptides (11). 
 The MA protein 
 
 The MA protein is always located at the amino (N)-terminus of the Gag 
polypeptide, and myristylation of this protein occurs at the glycine residue after 
the first methionine residue is removed (93,202).  Myristate is a 14-carbon fatty 
acid that is co-translationally added to certain proteins that are associated with 
plasma membranes.  The MA protein is cross- linked to phospholipids in the 
virion, closely associated with the plasma membrane, and seems to be a peripheral 
protein, which is supported by the lack of hydrophobic stretches of amino acids 
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found in integral membrane proteins (168).  In addition to myristylation, the MA 
protein contains regions of basic residues that also interact with the plasma 
membrane.  The MA protein therefore is thought to target the immature virion to 
the plasma membrane to promote viral assembly and budding. 
 The CA protein 
 The CA protein is the major structural protein of the viral core that 
surrounds the NC protein and the genomic RNA, but the structure and function of 
the core shell has not yet been determined (52)  This protein is a hydrophobic, 
phosphorylated protein that contains a 20 amino acid stretch called the major 
homology region (MHR) found in all retroviruses, except spumaviruses.  The 
MHR is thought to play a role in the formation of virions (219). 
 The NC protein 
 The NC protein is a small basic protein of 95 amino acids in length that is 
found tightly bound to the genomic RNA in the virion.  The protein contains a 
conserved motif of cysteine and histidine residues in the sequence CX2CX4HX4C 
(CCHC) that is found either once or twice in all retroviruses, except the 
spumaviruses.  This motif is similar to the zinc finger domains found in proteins 
capable of binding both zinc ions and nucleic acids.  The binding of zinc to the 
NC protein has been shown (11).  The genomic RNA is not detected in virions 
that do not contain the CCHC motif in the NC protein; therefore, this motif is 
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thought to bind to the 5’ end of the genomic RNA.  The NC protein also assists in 
the annealing of the tRNA primer to the genomic RNA as well as in the formation 
of the RNA dimer.  The basic stretches of NC amino acids are likely to be 
responsible for these functions as well as participation in the assembly and 
budding of the virion (232). 
 
 1.3.4.2 Proteins expressed from the pro and pol genes 
 
 
 Like the gag gene, the pro and pol genes are translated from the full-
length genomic RNA.  However, one and two -1 frameshifts, respectively, are 
required to produce the polypeptides from which the mature proteins (PR, RT,  
and IN) are cleaved.  Each of these proteins has enzymatic activity and, due to the 
low frequency of frameshifting, they are found in correspondingly lower levels 
than the structural proteins translated from the full- length MMTV genome (105). 
 The PR protein 
 The PR protein is responsible for the cleavage of the precursor 
polypeptides, which occurs either during budding or immediately after budding.  
The PR protein cleaves at mostly hydrophobic regions that are seven to eight 
residues in length, although the target sequences are variable (167).  The sequence 
of the PR protein resembles the aspartic proteases that contain two aspartate 
residues around their active sites; however, the retroviral PR proteins are only 
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active as a dimer, whereas the aspartic proteases are active as monomers.  This 
dimerization structure is thought to be important in keeping the enzyme inactive 
until virion assembly (208). 
 The RT protein 
 
 The RT protein is a highly conserved enzyme among retroviruses that is 
comprised of three enzymatic activities found in different domains.  The 
enzymatic activities associated with the RT protein are the RNA-dependent or 
DNA-dependent DNA polymerase, which are used by the virus for double-
stranded DNA synthesis from the single-stranded RNA.  This polymerase domain 
is located in the first two-thirds of the RT protein, and polymerase activity 
requires a primer to initiate DNA synthesis as well as a divalent cation.  Another 
enzymatic activity is the RNase H activity which is used by the virus to degrade 
the RNA portion of the RNA-DNA hybrid during reverse transcription (228). 
 The IN protein 
 The IN protein comprises the carboxy (C)-terminus of the cleaved Pol 
polyprotein and is less conserved compared to RT.  This protein functions in the 
integration of the proviral DNA into the host genomic DNA.  The IN protein 
contains a zinc finger domain that allows the protein to bind specifically to the att 
sites located at the ends of the proviral LTRs.  Once bound to the proviral DNA, 
two nucleotides from the 3’ end of the DNA are removed.  The 3’ OH ends attack 
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cellular DNA in an IN-catalyzed reaction at relatively random locations that are 6 
base pairs (bp) apart on opposite strands.  The IN protein then catalyzes the 
joining of the recessed 3’ OH termini of viral DNA to the phosphates of cellular 
DNA.  Subsequently, cellular enzymes are required to repair the chromosomal 
breaks and complete the viral integration event (239). 
 
 1.3.4.3 Proteins expressed from the env gene  
 
 
 The env gene is translated from a singly spliced transcript that is initiated 
from a promoter in the U3 region to produce a precursor polypeptide.  The 
nascent precursor contains a leader sequence at the N-terminus that is bound by 
the signal recognition particle and directed to the membrane of the rough 
endoplasmic reticulum (ER).  Translation of the polypeptide into the lumen of the 
ER continues until the polypeptide is anchored to the membrane of the ER 
through a hydrophobic domain at the C-terminus (53).  This Env protein is 
transported from the ER to the plasma membrane through the Golgi apparatus, 
which also is the site for cleavage by a cellular protease.  The two cleaved 
proteins then are located in the lipid envelope as a dimer held together by 
disulfide bonds and noncovalent interactions.  The Env protein dimer probably 
functions to bind to receptors on host cells and allow penetration of the virus (58). 
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 The SU protein 
 The SU protein is N-glycosylated after transport through the Golgi 
apparatus and is responsible for binding to host cell receptors.  The mouse 
transferrin receptor 1 (mTfR1) constitutes at least one host receptor for MMTV, 
and is recognized by the SU N-terminus (194,260).  The SU protein is the larger 
of the two Env proteins and is only associated with the virion through its 
interaction with the TM protein. 
 The TM protein 
 The TM protein spans the plasma membrane, or lipid envelope, through a 
hydrophobic region near the C-terminus.  This protein also contains a cytoplasmic 
domain, or “tail”, located on the internal side of the viral membrane, and this tail 
appears to contact the MA protein for viral assembly.  The TM protein also is N-
glycosylated, although not as heavily as SU (182). 
 
 1.3.4.4 Protein expressed from the sag gene  
 
 The Sag protein 
 MMTV contains an additional ORF called superantigen or Sag in the U3 
region of the 3’ LTR that is translated from a singly spliced transcript initiating 
from an internal env promoter (59).  MMTV is the only known retrovirus that 
encodes this protein (2).  Sag is a class II membrane protein synthesized in the ER 
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that undergoes proteolytic processing, possibly by furin or other protein 
convertases, as it is transported to the B cell membrane (51,95,185).  The 
processed Sag then is expressed on the surface of B cells in association with the 
major histocompatibility complex (MHC) class II molecules where it binds to the 
variable portion of the beta chain (Vβ) on T-cell receptor (TCR) molecules.  The 
Sag C-terminus is variable among different MMTV strains, and each Sag reacts 
with specific Vβ chains (253,257).  Most other antigens are presented by the MHC 
molecules of B cells and must bind both the variable portion of the α-subunit and 
the Vβ chain of TCR molecules.  The binding of Sag to only the Vβ chain 
therefore allows stimulation of larger numbers of T cells.  This stimulation is 
believed to be required for amplification of the infected lymphoid cell population 
(90). 
 
1.3.5 MMTV replication cycle 
 
 
 1.3.5.1 Attachment 
 
 MMTV, like all viruses, must attach to specific receptor molecules located 
on the host cell surface.  This interaction occurs between MTVR1 (mTfR1) and 
the receptor-binding domain near the N-terminus of the Env glycoprotein SU.  
TfR1 is a type II, single transmembrane glycoprotein expressed by different 
species for iron uptake.  Although multiple species express TfR1, MMTV is 
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specific for the rodent transferrin receptors, such as mTfR1 and rat TfR1 
(194,260).  Another MMTV receptor, MTVR2, mapped to mouse chromosome 
19, whereas MTVR1 mapped to chromosome 16 (73).  However, MTVR2 was 
unable to confer infection levels on virus-resistant cells comparable to mouse 
cells even when highly expressed, suggesting that this protein is a low-affinity 
receptor.  Alternatively, MTVR2 may concentrate virus on the surface of the cell, 
allowing entry through a non-receptor-mediated pathway (73). 
 
 1.3.5.2 Penetration/Uncoating 
 
 
 MMTV requires host cell uptake to release genomic RNA into the 
cytoplasm where replication can begin.  Most retroviruses undergo fusion with the 
plasma membrane of the host cells after attachment using a conformational 
change in their glycoproteins that exposes hydrophobic regions of the TM protein 
(57).  Other retroviruses, as well as many other enveloped viruses, require an 
acidic environment to produce the conformational change that allows fusion.  
mTfR1 on the host cell normally binds transferrin and then is endocytosed into 
clatherin-coated pits that traffic to the acidic endosome.  MMTV is dependent 
upon an acidic pH for membrane fusion, and acidified endosomes are required for 
infection.  Therefore, MMTV may bind mTfR1 to allow trafficking to the acidic 
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endosome, where the low pH induces the conformational change necessary for 
membrane fusion and subsequent uncoating of the virus (194). 
 
 1.3.5.3 Reverse transcription/Integration 
 
 
 MMTV replication is initiated after uncoating of the virus releases the 
core into the cytoplasm.  Once the genomic RNA is released, the proteins 
associated with the RNA are able to begin reverse transcription (Fig. 1.4).  The 
RT protein initiates DNA synthesis from the tRNAlys3 primer annealed to the PB 
on the 5’ end of the genomic RNA (144).  The genomic RNA then is copied into a 
minus-strand DNA, which contains sequences complementary to the R and U5 
regions.  The RNase H activity of RT degrades the RNA portion of the RNA-
DNA hybrid, leaving single-stranded sequences called the minus-strand strong-
stop DNA (187,228).  The minus-strand strong-stop DNA is transferred to the 3’ 
end of the genomic RNA where the complementary sequence of R binds to the R 
sequence found in the genomic RNA.  Synthesis of the minus-strand DNA 
continues to the 5’ end of the genome (the PB).  RNase H degrades most of the 
remaining RNA genome except for the PPT and other possible 
oligoribonucleotide primers.  The PPT or other primers then are used by RT to 
copy the minus-strand DNA into plus-strand DNA, and during RT 
polymerization,  the  primers  are  specifically  cleaved and degraded by RNase H. 
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Fig. 1.4. DNA proviral synthesis by reverse transcriptase. 
 
 See text for details. [Adapted from Principles of Virology 2004 (64)] 
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The newly synthesized plus-strand DNA contains the U3, R, and U5 regions as 
well as the first 18 nucleotides of the tRNA.  RNase H removes the tRNA from 
the RNA-DNA hybrid leaving plus-strand strong-stop DNA containing sequences 
complementary to the PB sequence at the 3’ end of the minus-strand DNA.  The 
plus-strand strong-stop DNA is transferred to the 3’ end of the minus-strand, 
which is elongated by displacement synthesis.  Subsequently, synthesis of the 
plus-strand and minus-strand DNAs are completed to form a linear double-
stranded DNA, or provirus (187). 
 The linear double-stranded DNA synthesized by reverse transcription 
contains the viral genes flanked by LTRs consisting of the U3, R, and U5 regions.  
This DNA is still associated with many of the viral proteins, including IN, and 
forms a preintegration complex (243).  Both LTRs contain inverted repeats at 
each end that are signals for IN to bind and cleave two nucleotides from the 3’ 
ends of the viral DNA leaving a two base pair overhang and a 3’ OH end (238).  
The complex then enters the nucleus during mitosis when the nuclear membrane 
is disassembled.  The 3’ OH ends of the viral DNA are used by IN to attack 
phosphodiester bonds on opposite strands of the host DNA that are 6 bp apart.  
The gaps created from integration are repaired and ligated by cellular enzymes, a 
process which also displaces the two 5’ nucleotides of the viral DNA that do not 
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match the host DNA.  The integrated proviral DNA is the template for 
transcription of the viral genomes (120). 
 
 1.3.5.4 Proviral expression 
 
 
 The MMTV provirus utilizes the host cell transcriptional and translational 
machinery for expression of transcripts and proteins, respectively.  Reportedly, 
MMTV has several promoters for mRNA synthesis: two in the LTR and two in 
the env gene (Fig. 1.5).  A promoter in the U3 region of the LTR is used to 
produce genomic and env mRNAs.  The genomic RNA is capped and 
polyadenylated by host cell enzymes, and this RNA can then be used for 
packaging into virions or as mRNA for the translation of the Gag, Pro, and Pol 
polyproteins.  Splicing of a portion of the genomic RNA also produces a singly 
spliced mRNA for translation of the Env precursor.  The two U3 promoters and 
the two env promoters are all able to transcribe sag mRNAs.  The mRNAs 
produced from the U3 promoters are singly spliced, whereas mRNAs synthesized 
from the env promoters may be singly spliced or unspliced (Fig. 1.5).  The 
biological significance of multiple sag mRNAs remains to be determined 
(59,79,155). 
 The mRNAs then are transported to the cytoplasm for translation.  The 
full- length genome RNA is translated by free polyribosomes into three precursor 
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proteins, Gag, Gag-Pro, and Gag-Pro-Pol, as previously described (105).  Both 
env and sag mRNAs are translated on membrane-bound polysomes to allow 



















Fig. 1.5. Diagram of the MMTV mRNAs. 
The MMTV provirus is shown with the LTRs as green boxes and the 
proteins as blue rectangles.  MMTV promoters are represented by pink 
ovals.  The mRNA transcripts expressed by MMTV are shown below 
the provirus as dashed lines.  Splice donors (SD) and splice acceptors 
(SA) are indicated by black lines, and introns are shown as dotted lines 
in the shape of a V.  Primers used to detect novel mRNAs are 
indicated above the gag-pol mRNA [Adapted from Mustafa et al, 2000 
(155)]. 
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 1.3.5.5 Viral assembly 
 
 
 Although little is known about the mechanism of assembly, MMTV viral 
assembly begins in the cytoplasm to form an immature type A particle that then is 
transported to the plasma membrane for budding.  It is thought that the Gag 
polyproteins interact with one another to initiate assembly of a virion, and the 
Gag-Pro and Gag-Pro-Pol polyproteins are recruited to the Gag polyprotein 
through targeting signals in the Gag portion of the polyprotein (145).  The NC 
section of the Gag polyprotein appears to be responsible for packaging of the 
genomic RNA (123).  Once the capsid associates with RNA, membrane-binding 
domains located in the MA portion of the Gag polyprotein target and direct the 
capsid to the membrane through an unknown mechanism.  At the membrane, the 
MA portion interacts with the Env glycoproteins to allow budding.  Release of 
virions from the plasma membrane is likely to involve a “late domain” containing 
the PSAP/PTAP sequences (176).  During or immediately after budding, the PR 
protein cleaves the polyproteins in the final maturation step producing a mature 
virion (55). 
 
1.3.6 MMTV life cycle 
 
 
 MMTV is transmitted from an infected mother to newborn pups through 
the milk (Fig. 1.6).  The virus passes though the stomach to the intestine where it 
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encounters B and T cells in the gut-associated lymphoid tissue (GALT) (142,255).  
MMTV infects B cells in the GALT, and these B cells then express Sag on the 
surface in association with the MHC class II molecule.  This complex allows Sag 
to bind specific Vβ chains on the TCR molecules that stimulates a large number of 
T cells to produce cytokines and induces the proliferation of infected B and T 
cells(1,6,72).  These infected B and T cells traffic to and infect dividing mammary 
gland cells.  The infected mammary gland cells then produce MMTV virions that 
can be shed into the milk.  A byproduct of high numbers of proviral insertions, 
some near cellular proto-oncogenes, in mammary cells is induction of breast 
cancer (72). 
 A number of transcriptional regulatory elements have been identified in 
the MMTV LTR, e.g., several negative regulatory elements (NREs), a hormone 
response element (HRE), and a mammary gland enhancer, that allow tissue-
specific MMTV expression (26,135,151).  The NRE contains binding sites for 
two transcription factors, special AT-rich sequence binding protein 1 (SATB1) 
(128) and CCAAT displacement protein (CDP) (262).  SATB1 is expressed 
primarily in lymphocytes and suppresses MMTV transcription in these cells 
(34,128).  CDP is a ubiquitously expressed protein that is found in 
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Fig. 1.6. Life cycle of exogenous MMTV. 
 
MMTV is transmitted from an infected mother to newborn pups 
through the milk.  The virus travels through the stomach and passes 
through M cells to the gut-associated lymphoid tissue (GALT).  B-
cells in the GALT are infected by MMTV particles and express Sag on 
their surface in association with MHC class II molecules.  Sag 
interacts with TCR molecules causing activation and proliferation of 
infected B and T cells.  These infected cells traffic to the mammary 
gland and infect dividing mammary epithelial cells. The infected 
mammary gland cells then are able to produce MMTV virions that can 
be shed in the milk and transmitted to pups.  Tumor development is 
likely to be a byproduct of multiple integrations sustained during peak 
viral replication during lactation. 
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SATB1 and CDP appear to suppress MMTV transcription throughout the viral 
life cycle until the mammary gland begins lactation (263). 
 The HRE and mammary gland enhancer both act as stimulators for 
MMTV expression in the mammary gland.  The mammary gland enhancer 
increases MMTV RNA levels in mammary cells although the levels and identities 
of the bound factors are not well characterized (151).  The HRE contains binding 
sites for steroid hormone receptors, which bind glucocorticoids and other steroid 
hormones (e.g., progesterone) that stimulate MMTV expression during pregnancy 
and lactation (86).  The increased MMTV expression observed in the mammary 
gland ensures that a large number of MMTV virions will be produced in the milk 
for infection of newborn pups (151). 
 MMTV does not encode an oncogene, and therefore, integrations near 
cellular oncogenes and transcriptional disregulation of these oncogenes are 
required for tumorigenesis (72,236).  Common integration sites, such as the Wnt 
family, the Fgf family, and the Notch family of genes, have been identified for 
mammary tumors induced by MMTV (77,111,188).  Retroviruses randomly 
integrate into host DNA; thus, tumor induction occurs largely in cell types with 






1.4 RNA EXPORT 
 
 
1.4.1 Cellular export 
 
 
 All retroviruses require the export of both spliced and unspliced mRNAs 
for replication and the use of cellular export machinery.  Cellular RNA is 
synthesized, processed, and assembled into a ribonucleoparticle (RNP) in the 
nucleus, but the RNP must be transported to the cytoplasm for RNA function.  
Little is known about RNA export, particularly mRNA export, and therefore, 
comparisons have been made with other transport mechanisms.  Recent evidence 
indicates that a number of RNA export mechanisms are dependent upon the 
export of proteins (156,222). 
 Import or export of any macromolecule occurs through the nuclear pore 
complex (NPC), which is located in the nuclear membrane (125,156,184).  The 
NPC consists of several proteins called nucleoporins and contains a central 
channel through which these macromolecules, such as proteins, can be 
transported.  For bi-directional transport, macromolecules must bind directly or 
through adaptor proteins to soluble transport receptors that target phenylalanine-
glycine (FG) repeats on the nucleoporins (62,143,195,217). 
 Three types of transport receptors have been discovered and most belong 
to the karyopherin, or importin/exportin family, while the others involve a nuclear 
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transport factor 2 (NTF2)/p10 complex or the Tip-associated protein 
(TAP)/Mex67 family (244).  The karyopherin family allows for transport of 
proteins containing nuclear localization signals (NLS) and nuclear export signals 
(NES), but also is involved in the transport of several classes of RNA (147,184).  
Since the karyopherins contain both importins and exportins, they are dependent 
upon the Ran GTPase cycle for directionality (Fig. 1.7).  A guanine nucleotide 
exchange factor (RanGEF), also located in the nucleus, acts on Ran so that the 
predominant form in the nucleus is RanGTP.  RanGTP binds to import receptors 
and signals the dissociation of the macromolecule from its receptor, which allows 
transport into the nucleus.  The RanGTP-receptor complexes then return to the 
cytoplasm.  For export of macromolecules, RanGTP in the nucleus assists in the 
binding of the macromolecule to the export receptor.  Once transport to the 
cytoplasm has occurred, the cytoplasmic GTPase-activating protein and its 
coactivator Ran-binding protein 1 hydrolyzes RanGTP to RanGDP.  RanGDP 
then signals the export receptor to dissociate from the macromolecule, thereby 
releasing it into the cytoplasm.  The transport receptor NFT2/p10 imports Ran 








Fig. 1.7. Regulation of protein transport by the Ran GTPase cycle. 
Step 1:  Importin (green) binds to a cargo macromolecule (red) in the 
cytoplasm and targets the nuclear pore complex (NPC) (purple) for 
import to the nucleus.  Step 2:  RanGTP in the nucleus binds to the 
importin/cargo complex, causing the release of the cargo 
macromolecule.  Step 3:  RanGTP also binds exportin (dark blue) in 
the nucleus, which assists in the binding of the exportin to cargo 
macromolecules destined for export.  This exportin/cargo complex 
binds the NPC to exit the nucleus.  Step 4:  RanGTP is hydrolyzed to 
RanGDP in the cytoplasm and dissociates the cargo from exportin.  




 RNA export is divided into four different classes that depend on the 
specific type of RNA:  mRNA, rRNA, U snRNA, and tRNA.  Each of these 
classes blocks their own export in saturating conditions, but not that of any other 
class, suggesting that each class uses its own export system (107,156).  The 
karyopherin family is used for export of the rRNA, U snRNA, and tRNA classes, 
but an mRNA-specific exportin that allows export has not yet been discovered.  
Export of rRNA in the form of ribosomal subunits and 5S rRNA also is not well 
characterized.  The export of ribosomal subunits has been difficult to analyze due 
to their complexity, but it has been shown that the Ran GTPase cycle is necessary 
and that the exportin chromosome region maintenance 1 (Crm1) protein is 
potentially involved (97,154).  The export of 5S rRNA also likely involves Crm1 
in addition to two 5S rRNA-binding proteins, TFIIIA and L5.  However, 
interactions between these proteins and the exportin have not yet been 
demonstrated, and other unidentified proteins are involved since 5S rRNA 
mutants unable to bind to TFIIIA are exported (143,156).  U snRNA export 
involves the 5’ m7G cap structure bound to mRNA as well as a nuclear cap-
binding complex (CBC) consisting of CBP20 and CBP80.  The CBC binds to the 
cap after addition to mRNA and then interacts with Crm1 for export of the U 
snRNAs (104,107).  Export of tRNA is unique among the RNA export systems 
because tRNA binds directly to the exportin and does not require adaptor proteins.  
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Only tRNA that has been processed and contains a mature terminus is capable of 
binding to exportin- t, which then transports it to the cytoplasm (7,119). 
 Export of mRNA is a complicated and mysterious process, yet export 
appears to be linked to post-transcriptional processing of mRNAs.  The pre-
mRNAs transcribed in the nucleus go through 5’ capping, polyadenylation, as 
well as splicing to form fully processed mRNAs.  RNA-binding proteins 
differentiate between these pre-mRNAs and fully processed mRNAs and bind to 
the fully processed mRNAs to form RNP, which then can be exported to the 
cytoplasm (125,244).  Cellular mechanisms enable only the fully-processed 
mRNAs to be exported.  These mechanisms include nonsense-mediated decay, 
which is used to degrade mRNAs containing premature stop codons, and a 
retention mechanism that does not allow export of mRNAs containing introns 
(157,250). 
 Some of the first proteins identified for mRNA export were the 
heterogeneous nuclear ribonucleoparticle (hnRNP) proteins since these proteins 
could both shuttle between the nucleus and cytoplasm and bind to mRNAs 
(172,173).  One protein, hnRNP A1, contains a sequence (M9) with both an NLS 
and an NES and was dependent on the karyopherin transportin.  It was also shown 
that saturating amounts of a peptide able to bind to the M9 sequence could inhibit 
 44 
export of dihydrofolate reductase (DHFR) mRNA, suggesting a role for export in 
a subset of the mRNAs (103,184). 
 The majority of mRNAs are not exported by hnRNPs; therefore, other 
proteins are involved in mRNA export.  Mex67 was recognized as an mRNA 
export protein in yeast due to the nuclear accumulation of mRNA in Mex67 
mutants (109,204).  The human protein TAP is an orthologue of Mex67 and also 
appears to be involved in cellular mRNA export.  TAP was shown to bind to a 
constitutive transport element (CTE) necessary for export of some retroviral 
RNAs, and excess CTE sequences blocked the export of mRNAs (78,166).  The 
Mex67/TAP family of proteins are independent of the karyopherin family and do 
not require Ran GTPase, yet they still shuttle between the nucleus and cytoplasm 
and bind to FG repeats of the nucleoporins (38,110). 
 Initially, the Mex67/TAP family proteins were thought to bind directly to 
mRNAs, although this interaction is weak.  Thus, it was suggested that mRNA 
export depended on adaptor proteins.  The Yra1 protein was identified in yeast as 
a protein with binding activity for mRNA and Mex67, and it also has an 
orthologue (Aly/Ref) in metazoans (177,220).  Aly/Ref was first identified as a 
cofactor for the transcription factors LEF-1 and AML and has since been shown 
to bind directly to TAP (33,221).  Recombinant Aly/Ref in Xenopus oocytes 
promotes mRNA export and antibodies against Aly/Ref specifically inhibit 
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mRNA export, supporting a role for Aly/Ref in the export of mRNAs.  Aly/Ref 
also provides an important link between RNA export and post-transcriptional 
processing.  Multiprotein complexes, including Aly/Ref, form on spliced mRNAs, 
but not on mRNAs from cDNAs, and Aly/Ref then may direct the RNP to TAP 
for export (190,261). 
 Many mRNAs need to be exported, and another pathway may involve the 
export of mRNAs containing adenosine/uridine-rich elements (AREs) in their 3’ 
untranslated regions.  The RNA-binding protein HuR and phosphoproteins April 
and pp32 all bind to ARE-containing mRNAs, and HuR was shown to use two 
different export systems (30,68,244).  HuR binds directly to transportin 2 through 
a shuttling sequence, but also uses the Crm1 pathway, possibly through 
interactions with April and pp32.  This pathway may regulate mRNA export 
since, in response to heat shock, HuR loses its ability to bind transportin 2 and 
interacts more readily with Crm1.  Because most of the heat shock mRNAs 
contain ARE elements, it is possible that HuR regulates the export of these 
mRNAs (29,67,125). 
 
1.4.2 Complex retroviral RNA export 
 
 
 All retroviruses require the export of both spliced and unspliced mRNAs 
for replication.  Unspliced mRNA serves as both the genomic RNA and the 
 46 
mRNA for production of the gag and pol gene products.  Complex retroviruses, 
such as HIV-1 and human T-cell leukemia virus type 1 (HTLV-1), also express 
singly spliced mRNAs in addition to completely spliced mRNAs.  Cellular 
mechanisms only allow the export of completely spliced mRNAs; therefore, 
complex retroviruses must employ other methods to export their unspliced and 
singly spliced mRNAs (46,134,229). 
 Completely spliced mRNAs of complex retroviruses are exported using 
normal cellular pathways and are translated into regulatory proteins (46,94).  One 
regulatory protein, HIV-1 Rev, was the first to be identified for retroviral RNA 
export, and proteins from other complex retroviruses (e.g., HTLV Rex1 and Rex2 
and HERV-K Rec) have since been identified that also function in RNA export 
(84,133,174).  These proteins bind to a cis-acting sequence found in unspliced and 
singly spliced mRNAs and subsequently facilitate their export into the cytoplasm.  
These cis-acting sequences are the Rev-response element (RRE) (Fig. 1.8), the 
Rex-response element (RxRE), and the Rec-response element (RcRE) for HIV-1, 













Fig. 1.8. Proposed structure of the Rev-response element (RRE). 
 
The RRE is drawn as an RNA element containing several stem loop 
structures using the generally accepted nomenclature.  The high-
affinity binding site in the second stem loop for Rev is boxed.  





 The Rev and Rev-related proteins must shuttle between the cytoplasm and 
the nucleus for RNA export.  The N-terminus of each of these proteins contains a 
stretch of basic amino acids, mostly arginines, which acts as an NLS and 
nucleolar localization signal (Fig. 1.9) (39,206).  Most NLSs bind to importin-α, 
which leads to interactions with importin-β , and this complex targets the NPC for 
translocation into the nucleus.  However, the Rev and Rex NLSs bypass the need 
for importin-α and have been shown to either directly bind importin-β or be 
imported in the absence of importin-α, respectively.  Once the proteins have been 
transported into the nucleus, importin-β  interacts with RanGTP to dissociate the 
complex that delivers Rev or Rex to the nucleus (24,75,91,234).  The NLS 
domain also functions as an RNA-binding domain (RBD) once the protein enters 
the nucleus and is dissociated from importin-β , and the Rev RBD binds to a high-
affinity binding site in the second stem loop of the RRE (see Fig. 1.9).  This 
bifunctional domain ensures that Rev and Rex are not bound to viral mRNAs after 
import into the nucleus, an event that could be harmful to viral replication 
(88,89,94). 
 Rev binds to the RRE as a monomer, but must multimerize for correct 
function.  These multimers form through domains that allow protein-protein 
interactions as well as secondary binding sites on the RRE.  Little is known about 
Rex multimer formation, although it is thought to be important for Rex function 
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(48,137,231).  After multimer formation on the RNA, this RNP complex then is 
targeted for cytoplasmic export by the activation domain or the NES (Fig. 1.9).  
The NES contains hydrophobic amino acids, usually leucines, which are relatively 
evenly spaced, although different NES-containing proteins show sequence 
variability.  The NES of these proteins then binds to Crm1 in the presence of 








Fig. 1.9. Domain organization of trans-acting factors used in RNA transport. 
HIV-1 Rev, HTLV-1 Rex, and HERV-K Rec are all trans-acting 
factors identified in viral RNA export.  Each protein contains an 
NLS/RNA-binding domain near the N-terminus which functions in 
nuclear import and binding of the protein to RNA elements on 
incompletely spliced mRNAs.  An NES/Activation domain is located 
towards the C-terminus and functions in exporting the protein/RNA 
complex to the cytoplasm.  Rev and Rex also contain multimerization 
domains important for protein function. 
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1.4.3 Simple retroviral RNA export 
 
 
 Simple retroviruses, like complex retroviruses, express a spliced mRNA 
that uses cellular pathways for export to the cytoplasm and unspliced and partially 
spliced mRNAs that must use a viral mechanism for export.  However, unlike the 
complex retroviruses, simple retroviruses do not encode a regulatory protein like 
Rev to export partially spliced mRNAs.  Instead, such viruses contain a cis-acting 
element or CTE that interacts with cellular proteins for export of the unspliced 
mRNA (45,46,83). 
 The CTE was first discovered in Mason-Pfizer Monkey virus (MPMV) 
when a viral sequence was shown to substitute for the Rev and the RRE in the 
expression of HIV proteins from a Rev-dependent RNA (28).  This element is 
located in the intragenic region between the env gene and the 3’ LTR, and CTE 
deletion resulted in the accumulation of unspliced mRNA in the nucleus.  Spliced 
MPMV mRNAs lacking the CTE were exported to the cytoplasm, verifying that 
the CTE is important for unspliced mRNA export (60,61,162).  Additional simple 
retroviruses, e.g., the simian retrovirus type 1 and type 2 (SRV-1 and SRV-2) or 
intracisternal-A particle (IAP) elements, contain CTEs, and the SRV-1 CTE also 
has been shown to substitute for Rev and the RRE in the expression of HIV 
proteins (225,226,251,264).  The avian sarcoma/leukemia retroviruses 
(ASV/ALV) contain at least one copy of a direct repeat that functions as a CTE, 
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but no sequence homology has been observed between the ASV/ALV elements 
and the CTEs (162,163,256).  In addition, these elements appear to use different 
cellular export pathways (164). 
 The CTE is an RNA element that folds into a stem loop structure 
containing two single-stranded loops and a top loop (Fig. 1.10).  The two single-
stranded loops and adjacent sequences are identical, but rotated 180o relative to 
each other, and mutations in either result in a loss of function for the MPMV and 
SRV-1 CTEs.  These results suggest that the loops may act as binding sites for 
cellular protein(s) involved in RNA export (45,60,83,226).  Since the CTE and 
Rev/RRE were interchangeable, it was expected that Crm1 would mediate RNA 
export through the CTE.  However, competition assays determined that the CTE 
was unable to compete with Rev or with 5S rRNA export, but instead competed 
with mRNA export.  Such experiments indicated that the CTE used a completely 
different pathway than Rev for RNA export (83,166,196). 
 Two cellular proteins that bound the CTE were identified as RNA helicase 
A and TAP.  The first protein to be identified was RNA helicase A, which was 
thought to have a role in CTE function since (i) it promoted CTE function if 
overexpressed and (ii) an excess of CTE RNA localized RNA helicase A to the 
cytoplasm.  However, antibodies against RNA helicase A were unable to prevent 




Fig. 1.10. Proposed structure of the constitutive transport element (CTE). 
The CTE is drawn as an RNA element that folds into a stem loop 
structure containing two single-stranded loops (shaded areas) and a top 
loop.  The shaded areas are identical but rotated 180o relative to each 
other.  These loops are the suggested binding sites for a cellular 
protein(s) involved in RNA export.  [Adapted from Cullen, 1998 (45)]. 
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effect on the Rev pathway.  Therefore, a role for RNA helicase A in CTE function 
has not yet been confirmed (126,166,229).  The second protein, TAP, was shown 
to bind to CTE RNA and also to increase cytoplasmic accumulation of CTE-
containing RNA in Xenopus oocytes.  TAP also plays a role in mRNA export 
since an excess of CTE RNA is capable of blocking mRNA export.  Cellular 
mRNAs do not contain RNA elements like the CTE and, most likely, use adaptor 
proteins for TAP binding and cytoplasmic export.  Therefore, the CTE may allow 
viral mRNAs to bypass earlier steps in the cellular mRNA export pathway and 
bind directly to TAP for export (45,78,83,166). 
 
1.5 RATIONALE FOR THIS STUDY 
 
 
 Current gene therapy methods generally use retroviral vectors, which 
allow both stable integration and high- level expression of the target gene; 
however, targeting of these vectors to specific cells is a disadvantage that has yet 
to be overcome.  Bacterial delivery systems target specific cells, yet gene delivery 
allows only transient expression.  The combination of these systems in gene 
therapy should allow stable gene expression in specific target cells.  Bacterial 
delivery systems able to translocate through M cells to Peyer’s patches should 
deliver an MMTV vector to B and T cells.  B and T cells carrying the MMTV 
vector might use Sag-specific amplification and trafficking of lymphoid cells to 
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deliver target genes to mammary glands.  Once in the mammary gland, the 
MMTV vector can express a therapeutic gene, such as IL-12, to target breast 
cancer cells. 
 In this study, different bacterial systems were developed for delivery of 
reporter genes to eukaryotic cells.  An MMTV reporter vector was constructed 
and characterized for use with these bacterial delivery systems to determine 
whether specific cell targeting and expression of the reporter gene could occur.  
Critical sites necessary for expression of MMTV-specific genes also were mapped 
by mutagenesis, and a trans-acting factor involved in RNA export was identified 












2. Materials and Methods  
2.1 BACTERIAL STRAINS 
 
 
 The bacterial strains used in this study are listed in Table 2.1. 
 




Strain Characteristics Source Location 
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     Escherichia coli 
DH5α invA DH5α derivative with Y. 
pseudotuberculosis invA 
gene integrated into the 
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 The transformation procedure for Shigella was modified from Dagert and 
Ehrlich (47) with a prolonged incubation in calcium chloride (CaCl2).  A red 
colony from a Congo red plate was inoculated into 50 ml Luria Broth (LB) with 
appropriate antibiotics and incubated at 37oC with shaking until the culture 
reached an A650 = 0.2.  The culture was heated to 50oC for 10 min and then was 
chilled on ice for at least 10 min.  The Shigella were centrifuged in a Sorvall SS-
34 rotor at 2000 x g for 10 min at 4oC, and the pellet resuspended in 20 ml cold 
0.1 M CaCl2 and incubated at 0oC for 20 to 25 min.  The bacteria were 
centrifuged at 2000 x g for 10 min at 4oC, resuspended in 0.5 ml cold 0.1 M 
CaCl2, and incubated overnight on ice at 4oC.  At least 500 ng DNA was added, in 
a volume smaller than 10 µl, to 0.1 ml competent Shigella and incubated on ice 
for at least 30 min.  The Shigella and DNA were subjected to heat shock at 42oC 
for 90 sec, and 1.5 ml LB was added prior to incubation at 37oC with shaking for 
1 hr.  The Shigella were centrifuged in a Microfuge 18 centrifuge (Beckman 
Coulter, Inc., Fullerton, CA) at 15000 x g and resuspended in a smaller volume, 
and the entire mixture was plated on Congo red plates with the correct antibiotics 
and incubated overnight at 37oC. 
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2.2.2 Escherichia coli  
 
 
 2.2.2.1 Calcium Chloride  
 E. coli were inoculated into a 5 ml LB culture without antibiotics and 
incubated overnight at 37oC with shaking.  This overnight culture (4 ml) then was 
used to inoculate 500 ml LB and incubated at 37oC with shaking until an A600 = 
0.4 to 0.45.  The E. coli were chilled on ice for 15 to 20 min and then centrifuged 
in an Avanti J-E centrifuge (Beckman) with a JA-20 rotor at 6000 x g for 10 min 
at 4oC.  The pellet was resuspended in 200 ml cold 0.1 M CaCl2, placed into four 
50 ml conical tubes, and incubated on ice for 20 min.  The E. coli were 
centrifuged in an IEC Centra CL3R centrifuge at 700 x g for 10 min at 4oC and 
resuspended in 5 ml cold 0.1 M CaCl2 containing 10% glycerol.  DNA (30 to 50 
ng) was added to 0.1 ml competent E. coli, mixed gently, and incubated on ice for 
30 min.  The bacteria and DNA were then subjected to heat shock for 90 sec at 
42oC, and 0.9 ml LB added and incubated for 1 hr at 37oC with shaking.  The E. 
coli were then plated onto LB plates containing the corresponding antibiotic to the 
plasmid resistance and incubated overnight at 37oC. 
 2.2.2.2 Electroporation 
 E. coli were inoculated into a 5 ml LB culture without antibiotics and 
incubated overnight at 37oC with shaking.  This overnight culture (2.5 ml) was 
then used to inoculate 500 ml LB and incubated at 37oC with shaking until an 
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A600 = 0.5 to 0.7.  The E. coli were chilled in an ice-water bath for 10 to 15 min 
and then transferred into prechilled centrifuge bottles.  The E. coli were 
centrifuged in a Sorvall GS-3 rotor at 2500 x g for 15 min at 4oC and resuspended 
in 500 ml cold H2O.  The bacteria were pelleted as before and resuspended in 250 
ml cold H2O, and this step then was repeated with 125 ml H2O, 50 ml H2O, and 
finally 50 ml H2O containing 10% glycerol.  The E. coli were pelleted, and all but 
3 to 6 ml of the supernatant was discarded.  The bacteria were resuspended in 3 to 
6 ml H2O containing 10% glycerol and aliquoted for use in an electroporation.  
Ten ng DNA were added to 100 to 200 µl electrocompetent bacteria which were 
placed in a prechilled 2 mm gap cuvette.  A BTX Electro Cell Manipulator 600 
(BTX, Inc., San Diego, CA) was used with the settings 2.45 kilovolts and R5 
(129O) to electroporate the DNA into the bacteria.  One ml LB was added 
immediately to the bacteria and incubated at 37oC with shaking for 1 hr, and the 
bacteria then were plated onto LB plates, containing the antibiotics corresponding 
to the plasmid resistance, and incubated overnight at 37oC. 
 
2.3 BACTERIAL INFECTIONS 
 
 
2.3.1 Shigella infection 
 
 
 Shigella ssp. containing an antibiotic resistance plasmid and the construct 
of interest were isolated on Congo red plates supplemented with 100 µg/ml 
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streptomycin, 50 µg/ml kanamycin, 45 µg/ml diaminopimelic acid (DAP), and an 
appropriate antibiotic for the antibiotic resistance plasmid.  The suspension cells 
were split 3 to 6 x 105 cells/ml so there would be 2 x 106 cells for each infection.  
On the day of the infection, 3 to 4 red colonies were isolated, and a starter culture 
was incubated in 1 ml LB containing the supplements indicated above for 1 hr at 
37oC with shaking.  Three hundred µl of the starter culture was used to inoculate 
5 ml of LB containing supplements and 2.5 mM deoxycholate, and the culture 
was grown at 37oC with shaking to an OD650 = 0.5 to 0.7.  A 1 ml sample of the 
culture was centrifuged at 15000 x g for 30 sec at room temperature (25oC) and 
resuspended in tissue culture medium (without antibiotics + DAP) to a final 
concentration of 2 x 108 colony-forming units (CFU)/100 µl.  The calculation was 
derived from the formula OD650 x 8 = CFU [x 108] x 50 = µl tissue culture 
medium needed to resuspend the pellet.  A larger sample of bacteria was 
centrifuged and resuspended with tissue culture media if needed.  Isolated 
lymphocytes (2 x 106) were resuspended in 5 ml of tissue culture media 
containing 30 µg/ml DAP, placed in a 15 ml conical tube, and 100 µl Shigella (2 
x 108) were added and mixed thoroughly.  The bacteria and lymphocytes were 
centrifuged at 1500 x g for 10 min at 25oC to bring them into close contact for 
attachment and invasion.  The cap of the 15 ml conical tube was loosened, and the 
tube was placed in a 5% CO2 incubator at 37oC for 45 min.  The pellet was 
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resuspended and incubation was continued for an additional 45 min at 37oC.  The 
cells were washed twice with phosphate-buffered saline (PBS), and 3 ml fresh 
media containing 100 µg/ml gentamycin without DAP was added.  The cells were 
incubated for 90 min at 37oC, washed once with PBS, then resuspended in 10 ml 
media with 50 µg/ml gentamycin.  The cells were placed in a 100 mm plate and 
incubated for 48 hr at 37oC prior to analysis. 
 
2.3.2 Yersinia infection 
 
 
 Adherent mammalian cells were split into 35 mm dishes the day before an 
infection to allow 60 to 70% confluence on the day of infection.  The Yersinia 
strains were grown in brain-heart infusion (BHI) medium (Difco Laboratories, 
Detroit, MI) containing 2.5 mM CaCl2 plus appropriate antibiotics at 26oC with 
shaking.  To initiate the experiment, the Yersinia cultures (1 ml) were washed 
with BHI medium containing 5 mM ethyleneglycol-bis N,N’-tetra acetic acid  
(EGTA) and 20 mM magnesium chloride (MgCl2).  The Yersinia were then 
diluted 50-fold with the same media plus 3 µl/ml o-Nitrophenyl-b-D-fucoside 
(ONPF), incubated 1 to 2 hr at 26oC with shaking, and shifted to 37oC for 1 hr 
with shaking.  Fresh medium containing 5 µg/ml cytochalasin D (CCD) was 
added to the adherent cells 30 min before the infection to stop the uptake of the 
bacteria.  The Yersinia cultures were centrifuged at 15000 x g for 30 sec at 25oC 
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and resuspended with an equal volume of tissue culture media without antibiotics.  
Two hundred µl of Yersinia was added to each well of adherent cells and 
centrifuged in an IEC Centra GP8 at 170 x g for 5 min at 25oC.  The mammalian 
cells and bacteria were then incubated in a 5% CO2 incubator at 37oC for 30 min, 
after which they were washed twice with PBS and incubated an additional 45 
minutes in fresh media containing 5 µg/ml CCD.  After the incubation, the cells 
were washed twice with PBS and incubated for 1 hr at 37oC in media containing 
50 µg/ml gentamycin.  The cells then were washed three times with PBS, and 
fresh media containing 20 mg/ml gentamycin was added to the cells and 
incubated for 48 hr. 
 
2.3.3 E. coli infection 
 
 
 2.3.3.1 Adherent cells 
 The day before the infection, adherent mammalian cells were split into 35 
mm plates, and E. coli strains containing the test construct were inoculated into 5 
ml LB with the appropriate antibiotics.  On the day of the infection, the E. coli 
strains were diluted 100-fold in LB plus antibiotics and grown to mid- log phase at 
37oC with shaking.  The bacteria were pelleted and resuspended to a 
concentration of 2 x 108 bacteria/ml in PBS.  The adherent cells were washed 
once with PBS, and 2 ml tissue culture media without antibiotics was added to 
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each well.  One hundred µl E. coli was added to each well, and the mammalian 
cells and bacteria were centrifuged in an IEC Centra GP8 at 170 x g for 5 min at 
25oC and incubated 90 min at 37oC in a 5% CO2 incubator.  The cells were 
washed 3 times with PBS, and 2 ml of tissue culture media plus 100 µg/ml 
gentamycin were added to each well and incubated for an additional 90 min at 
37oC.  This procedure was repeated in the presence of 20 µg/ml gentamycin and 
an incubation time of 48 hr prior to analysis of the cells. 
 2.3.3.2 Suspension cells 
 The day before the infection, the E. coli were inoculated using the protocol 
for infection of adherent cells into 5 ml LB with appropriate antibiotics, and the 
suspension cells were subcultured to approximately 5 x 105 cells/ml.  On the day 
of the infection, the E. coli strains were diluted 10-fold in 5 ml LB with 
antibiotics and incubated for 2 hr at 37oC with shaking.  The suspension cells 
were counted and resuspended to a concentration of 1 x 106 cells/1.5 ml tissue 
culture media without antibiotics and, when specified, 5 µg/ml CCD in 35 mm 
dishes.  The E. coli were resuspended to a concentration of 2 x 108 bacteria/100 µl 
tissue culture media according to the Shigella infection procedure, and 100 µl of 
the bacterial suspension was added to the appropriate wells.  The mammalian 
cells and bacteria were centrifuged at 170 x g for 5 min at 25oC and incubated at 
37oC for 90 min.  The cells were washed with PBS in 1.5 ml conical tubes by 
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centrifugation at 450 x g for 5 min at 4oC.  Infected cells were resuspended in 1.5 
ml tissue  culture media with 50 µg/ml gentamycin and incubated 1 hr at 37oC.  
The cells were washed again with PBS, resuspended in 1.5 ml tissue culture 
media with 50 µg/ml gentamycin, and incubated overnight at 37oC prior to 
analysis. 
 
2.4 CELL LINES 
 
 
 Jurkat human T cells were grown in RPMI medium (Invitrogen, Carlsbad, 
CA) supplemented with 7.5% fetal calf serum (FCS) (Invitrogen), 100 U/ml 
penicillin, 100 µg/ml streptomycin, and 50 µg/ml gentamycin.  A20 murine B 
cells, LBB.11 murine B cells (obtained from Dr. Brigitte Huber, Tufts University, 
Boston, MA), RLmale1 murine T cells, and EL4b murine T cells (obtained from 
Dr. James Allison, University of California, Berkeley, CA) were maintained in 
RPMI medium supplemented with 10% FCS, 100 U/ml penicillin, 100 µg/ml 
streptomycin, 50 mg/ml gentamycin, and 5 x 10-5 M 2-mercaptoethanol.  XC rat 
fibroblast cells were grown in Dulbecco’s modified Eagle’s medium (DMEM) 
(Invitrogen) supplemented with 5% FCS, 100 U/ml penicillin, 100 µg/ml 
streptomycin, and 50 µg/ml gentamycin.  293T human epithe lial cells were 
maintained in DMEM supplemented with 10% FCS, 100 U/ml penicillin, 100 
µg/ml streptomycin, and 50 µg/ml gentamycin.  Henle human epithelial cells 
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(obtained from Dr. Shelley Payne, University of Texas, Austin, TX) were grown 
in Minimum Essential Medium (MEM) supplemented with 10% FCS, 10% 




 Expression vectors were obtained commercially, provided by colleagues, 
or constructed in this study (Table 2.2).  Plasmids constructed in this study are 
described below. 
 The CTE-dependent luciferase vector was cloned using pRL-TK 
(Promega, Madison, WI) (Table 2.2).  The chimeric intron was removed by 
complete digestion of pRL-TK with HindIII and NheI followed by blunt end 
formation using Klenow enzyme (New England Biolabs, Beverly, MA).  The 
vector fragment containing the HSV TK promoter, luciferase gene, and antibiotic 
resistance gene was isolated by gel purification using Qiaquick gel extraction kit 
(Qiagen, Valencia, CA), and self- ligated to create pRL-TK∆intron (Table 2.2).  
The SV40 late poly(A) sequence then was replaced with the BGH poly(A) 
sequence in both pRL-TK and pRL-TK∆intron to increase luciferase levels.  To 
remove the SV40 late poly(A), both luciferase vectors were linearized with 
BamHI, followed by treatment with Klenow enzyme to create blunt ends and 
digestion   with   NotI.   The  vector  pcDNA3  (Invitrogen)  containing  the  BGH 
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Table 2.2. Plasmids obtained commercially or provided by colleagues. 
Plasmid Characteristics Source Location 
pHYB-MTV MMTV hybrid provirus in 










penvLTR/p19∆RI HindIII fragment from 
pHYB MTV containing the 
env gene and the 3’ LTR in 








pEGFP-C1 Eukaryotic GFP expression 
vector carrying the CMV 
promoter 
Clontech  Palo Alto, CA 
pJZ466 Eukaryotic GFP expression 








pCD3GFP Eukaryotic GFP expression 






pLR9 Prokaryotic GFP 
expression vector carrying 











pCMV-EGFP Eukaryotic GFP expression 






p19TLTR-EGFP Eukaryotic GFP expression 
vector carrying the TBLV 
LTR as the promoter 
This study  
pMMTV-GFP Eukaryotic GFP expression 
vector carrying the MMTV 







pGEMT-Easy Cloning system for PCR 
products 
Promega  Madison, WI 
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pGL2-Promoter Eukaryotic vector with 
firefly luciferase under the 
control of the SV40 
promoter 
Promega “ 
pIB29MEK Y. pseudotuberculosis 
virulence plasmid 
containing mutations in 








pSS351 Eukaryotic GFP expression 
vector carrying the CMV 
promoter 
“ “ 
pSS356 yopE promoter region and 
first 49 codons fused to lacI 
“ “ 
pSS357 pSS356 derivative; yopE 
promoter region and first 
49 codons fused to the first 
333 codons of lacI 
“ “ 
pLR56 Prokaryotic vector that 






pRL-TK Eukaryotic vector with 
Renilla luciferase under the 
control of the thymidine 
kinase  promoter 
Promega  
pRL-TK∆intron pRL-TK derivative with the 
chimeric intron deleted 
This study  
pRL-BGH pRL-TK derivative 
containing the BGH 
poly(A) sequence 
“  
p∆RL-BGH pRL-BGH derivative with 
the chimeric intron deleted 
“  
pTR224 pUC-based cloning vector 
containing the MPMV CTE 
“  
2-1 penvLTR/p19∆RI 
derivative containing the 




p19∆SalI pUC19 derivative with the 
SalI site removed 
“  
p19envd p19∆SalI derivative 
containing the MMTV env 
gene, the duplicated 
env/sag PCR fragment, and 
the MMTV 3’ LTR 
“  
p19envd-GFP p19envd derivative 
containing the IRES-GFP 
from pJZ466 
“  
pBR5’ pBR322 derivative 
containing the MMTV 5’ 
LTR and the gag and pol 
genes 
“  
pHYB-GFP pBR322 vector backbone 
with the MMTV provirus 
containing the env/sag PCR 















poly(A) was digested with NotI and the blunt cutter PvuII.  The luciferase 
fragments without the SV40 late poly(A) and the BGH poly(A) fragment were 
isolated by gel purification, and the BGH poly(A) fragment then was ligated with 
each luciferase fragment to create both pRL-BGH and p∆RL-BGH (Table 2.2). 
 The p∆RL-BGH vectors containing different MMTV fragments and the 
Mason-Pfizer Monkey Virus (MPMV) constitutive transport element (CTE) were 
constructed by linearizing p∆RL-BGH with NotI or XhoI.  The MMTV fragments 
were amplified by polymerase chain reactions (PCR) using primers from Table 
2.3 and cloned into the vector pGEMT-Easy (Promega).  Fragments were 
removed by digestion with NotI and then were cloned into the p∆RL-BGH vector 
that had been linearized with NotI.  The MPMV CTE was obtained from the 
vector pTR224, which was provided by Dr. Farah Mustafa (Table 2.2).  The 
MPMV CTE was isolated from pTR224 after digestion with XhoI and SalI and 
cloned into the p∆RL-BGH vector that had been linearized with XhoI.  All 







Table 2.3. Primers used in this study. 
Letter Primer Name Sequence (5’-3’) 
A EGFP for GCAAGCTGACCCTGAAGTTCATC 
B EGFP rev GGATCTTGAAGTTCACCTTGATGC 
C C3HLTR1+ ATGCCGCGCCTGCAGCAGAAATGGT 
D gag620- CCTCCAAATCATCCCAATCCTC 
E C3H230+ CATCACAAGAGCGGAACGGAC 
F pol4235- CAAGGGCTATTGCTCTCTTC 
G pol4235+ GAAGAGAGCAATAGCCCTTG 
H env6337- GGGCCCCTTTTGGAGAAAATGAGAGT 
I pol5835+ GCCACGCACTACATCATC 
J 2251env- CGTTAAGATCTGACTGCACTTGG 
K TBLVenv8509+ AGCCTTGACCAAGTGCAGTCAGATCTTAACGTG 
L 3’PBR3- CACCCTGTATATGAGTTCCC 
M C3Hpol6419+ CGAAAGACATTGGGGACC 
N C3HLTR112- TATGTCTTTGTCTGATGGGC 
O C3Henv7461- CCCATCCTGCTTCATACC 
P C3Henv7478+ GGTATGAAGCAGGATGGG 
Q env796- GCTTATCTACTTGAAAGCAGCCT 
R C3HLTR1169- GCAAGTTTACTCAAAAAATCAGCA 
S Gapdh427+ CATGTTTGTGATGGGTGTGAACCA 
T Gapdh983- GTTGCTGTAGCCGTATTCATTGTC 
U C3Henv7255+ ATCGCCTTTAAGAAGGACGCCTTCT 
V C3HLTR548- TACTTCTAGGCCTGTGGTCA 
W DHFR-1 FP-1 GGCGGAAACATTGGATGCGG 
X DHFR-1 RP-1 GACACTCTGTTATTACAAATCG 
Y RRE for GAGCAGTGGGAATAGTAGG 
Z RRE rev TCCCTAGGAGCTGTTGATCC 
AA IRES4066- ACCTTCTGGGCATCCTTC 
AB C3HLTR408- TCTACCTATTGGATTGGTCTTATTGG 
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 The green fluorescent protein (GFP)-tagged MMTV vector was 
constructed in several steps using PCR primers that contain restriction 
endonuclease sites (underlined) in the 5’ end for cloning purposes.  The sequence 
that is overlapped by both the env and sag genes was amplified by PCR using the 
sense primer (5’-GCA GTC AGA TCT TAA CGT GCT TC-3’) and the antisense 
primer (5’-CCG CGT CGA CTA GGT GTA GGA CAC TCT C-3’).  The PCR 
product was then used in another reaction using the same sense primer and the 
antisense primer (5’-GAA GAT CTC TGG AAA ACA AGC GGC CGC GTC 
GAC TAG GTG TAG GAC ACT C-3’) to create a fragment containing BglII 
sites on the flanking ends as well as internal SalI and NotI sites.  The PCR 
fragment was digested with BglII and cloned into the vector penvLTR/p19∆RI 
that had been linearized with BglII to create the vector 2-1.  To remove additional 
SalI sites, other than the one from the PCR fragment, this vector then was 
digested with HindIII and cloned into the HindIII site of p19∆SalI to create the 
vector p19envd.  The IRES-GFP fragment was removed from the vector pJZ466 
by digestion with NotI and SalI and cloned into p19envd that had been digested 
with NotI and SalI to obtain the vector p19envd-GFP.  pHYB-MTV was digested 
with ClaI, and the ca. 7.5 kb fragment containing the 5’ portion of MMTV was 
purified by agarose gel electrophoresis.  This fragment was cloned into pBR322 
that had been linearized with ClaI to generate the vector pBR5’.  The 3’ portion of 
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MMTV including the GFP-tagged env gene was then removed from p19envd-
GFP by digestion with BstBI and XbaI and isolated following agarose gel 
electrophoresis.  The 5.4 kb fragment was then cloned into pBR5’ digested with 
BstBI and NheI to create the final vector pHYB-GFP (Table 2.2). 
 
2.6 PLASMID PREPARATIONS 
 
 
2.6.1 Small-scale alkaline lysis 
 
 
 Two ml bacterial cultures were centrifuged in a Microfuge 18 centrifuge 
(Beckman) at 15000 x g for 30 sec at 25oC.  The pellet was resuspended in 310 µl 
Solution I (50 mM glucose, 25 mM Tris-HCl [pH 8.0], and 10 mM 
ethylenediaminetetraacetate [EDTA]) containing 400 µg/ml RNaseA, and 310 µl 
Solution II (0.2 N sodium hydroxide [NaOH] and 1% sodium dodecyl sulfate 
[SDS]) was added and gently inverted 5 to 6 times to mix and lyse the bacteria.  
After a 5 min incubation at 25oC, 310 µl Solution III (3 M potassium acetate [pH 
4.8]) was added and mixed thoroughly.  The sample was subjected to 
centrifugation at 15000 x g for 10 min at 25oC, and the supernatant was 
transferred to another Eppindorf tube.  Isopropanol (0.6 volume) was added to the 
supernatant to precipitate the DNA, and the sample was pelleted at 15000 x g for 
10 min at 25oC.  The pellet was washed with 70% ethanol, air-dried for 5 to 10 
min, and resuspended in 50 µl of 10 mM Tris-HCl (pH 7.4) and 0.1 mM EDTA 
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[TE (10:0.1)].  The concentration of the DNA was determined using a Beckman 
DU-6 spectrophotometer and absorbance readings at 260 nm and 280 nm. 
 
2.6.2 Large-scale alkaline lysis 
 
 
 Different large-scale preparations were used depending on the nature of 
the vector.  For pBR322-based plasmids, a colony or bacteria from a glycerol 
stock were used to inoculate 25 ml of LB containing 50 µg/ml appropriate 
antibiotics and incubated overnight at 37oC with shaking.  Twenty ml of the 
overnight culture was added to 500 ml of LB and grown at 37oC with shaking 
until an absorbance reading of 1.2 at 600 nm was obtained.  Chloramphenicol 
(Sigma, St. Louis, MO) was added to a final concentration of 170 µg/ml, and the 
bacteria were grown overnight at 37oC with shaking.  For all other plasmids, 500 
ml LB containing the appropriate antibiotic was inoculated with a colony or 
bacteria from a glycerol stock and grown overnight at 37oC with shaking for 12 to 
16 hr. 
 The bacteria were centrifuged in an Avanti J-E centrifuge at 6000 x g for 
10 min at 4oC, and the supernatant was discarded.  The pellet was resuspended in 
8 ml of Solution I (as described in section 2.6.1) containing 2 mg/ml lysozyme 
and transferred to a 50 ml conical tube.  Sixteen ml of Solution II (as described in 
section 2.6.1) was added, and the suspension was mixed well and incubated for 5 
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to 10 min at 25oC.  Twelve ml of cold Solution III (as described in section 2.6.1) 
was added and mixed by inverting the tubes several times.  The mixture was 
incubated on ice for 10 min, and the sample was centrifuged in an IEC Centra 
CL3R at 2850 x g for 30 min at 4oC.  The supernatant was strained through 
cheesecloth into a new 50 ml conical tube, and 70 µl RNaseA (10 mg/ml) was 
added.  To precipitate the DNA, 0.6 volume isopropanol was added to the 
supernatant, mixed well, and incubated at 25oC for 20 min.  The DNA then was 
centrifuged at 2850 x g for 30 min at 4oC, washed with 70% ethanol, and allowed 
to airdry for 5 to 10 min.  The pellet was resuspended in 3.3 ml of 10 mM Tris-
HCl (pH 7.4) and 10 mM EDTA [TE (10:10)], and 4.6 g CsCl was added and 
dissolved.  Four hundred µl ethidium bromide (EtBr) (5 mg/ml) was added, and 
the debris (RNA and protein) was removed by centrifugation at 2850 x g for 20 
min at 4oC.  The sample was added to a Beckman Optiseal tube and subjected to 
centrifugation in a Beckman L7 Ultracentrifuge at 220000 x g for 16 to 18 hr at 
20oC in an NVT 65.2 rotor.  The plasmid band was collected using a 5 ml syringe 
and an 18 gauge needle, and the EtBr extracted 3 to 4 times using 2 volumes of G-
50 buffer saturated with n-butanol.  A solution of TE (10:10) was added to a final 
volume of 5 ml, and the DNA was precipitated by adding 2 volumes ethanol and 
incubating at -20oC for 30 min.  The DNA was pelleted in an IEC at 2850 x g for 
30 min at 4oC, and the pellet was resuspended in 2 ml of 10 mM Tris-HCl (pH 
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7.4) and 1 mM EDTA [TE (10:1)].  The sample then was dialyzed against 2 L of 
TE (10:1) using a Slide-A-Lyzer dialysis cassette (Pierce, Rockford, IL), with 
buffer changes after 1 hr and overnight incubations.  The DNA was collected, 
ethanol precipitated, and washed with 70% ethanol before resuspending in TE 
(10:0.1).  The concentration of the DNA was determined using a Beckman 





2.7.1 Superfect transfection of suspension cells 
 
 
 Suspension cells were subcultured at approximately 3 x 105 cells/ml the 
day before the transfection.  The next day the cells were counted and, for each 
transfection, 1.25 x 106 cells were plated in 2.5 ml tissue culture medium in 60 
mm dishes.  Two µg test DNA plus 0.5 µg co-transfectant DNA was added to 75 
µl tissue culture medium without serum or antibiotics.  Ten µl Superfect Reagent 
(Qiagen) was added and mixed with the DNA, and the mixture was incubated for 
5 to 10 min at 25oC.  The Superfect-DNA mixture was added dropwise to the 







2.7.2 Superfect transfection of adherent cells 
 
 
 The day before the transfection, adherent cells were counted, and 
approximately 8 x 105 cells were plated into one well of a 6-well plate in tissue 
culture medium.  One µg test DNA plus 1 µg co-transfectant DNA was added to 
75 µl tissue culture medium without serum or antibiotics.  Ten µl Superfect 
reagent was added and mixed with the DNA, and the mixture was incubated for 5 
to 10 min at 25oC.  The cells were washed with 1X PBS, 1 ml complete tissue 
culture medium was added to the Superfect-DNA mixture, and approximately 1.1 
ml of the mixture was added to the cells and incubated for 2 to 3 hr at 37oC in an 
incubator with 7.5% CO2.  The medium was removed from the cells, 2 ml fresh 
medium was added, and the cells incubated for an additional 48 hr. 
 
2.7.3 DMRIE-C transfection of adherent cells 
 
 
 The day before the transfection, adherent cells were counted, 
approximately 2 x 105 cells were plated into one well of a 6-well plate in 2 ml 
tissue culture medium.  Ten µl of DMRIE-C reagent (Invitrogen) were mixed 
with 0.5 ml tissue culture medium without serum or antibiotics for each 
transfection and incubated for 10 to 15 min at 25oC.  Five µg test DNA plus 0.5 
µg co-transfectant DNA was mixed with 0.5 ml tissue culture medium without 
serum or antibiotics.  The DMRIE-C/medium mixture was added to the 
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DNA/medium mixture at a 1:1 ratio containing 0.5 ml of each mixture and 
incubated for 30 to 45 min at 25oC.  The adherent cells were washed twice with 
tissue culture media without supplements, and 1 ml transfection mixture was 
added to each well and incubated for 6 to 9 hr at 37oC in an incubator with 7.5% 
CO2.  The transfection was stopped by the addition of 1 ml complete tissue 






 Electroporations were performed using a BTX ECM600 electroporator.  
A20 cells were seeded at 6 x 105 cells/ml, and the next day, the cells were 
counted, and a suspension of 2.5 x 107 cells/ml was prepared in RPMI containing 
10% FCS.  Twenty µg test DNA was mixed with 400 µl (1 x 107 cells), and the 
mixture was added to a 4 mm gap cuvette and incubated for 10 min at 25oC.  Cells 
were subjected to electroporation using 280 V, 960 µF, and R4 (72O) and, 
subsequently, the sample was incubated on ice for 10 min.  The cells then were 
plated in 5 ml complete RPMI in 60 mm dishes and analyzed after 24 hr.  Jurkat 
cells were seeded at 5 x 105 cells/ml the day before the electroporation.  The next 
day the cells were counted, and a suspension of 1 x 107 cells/ml was prepared in 
RPMI containing 5% FCS.  One µg of reporter DNA and 2 µg of co-transfectant 
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DNA were added to 400 µl (4 x 106 cells), and the mixture was placed into a 4 
mm gap cuvette and incubated for 10 min at 25oC.  Conditions for electroporation 
were: 270 V, 1050 mF, and R10 (720O).  After electroporation, the sample was 
incubated at 25oC for 10 min before plating in 5 ml RPMI in a 60 mm dish.  Cells 
were harvested 48 hr after electroporation. 
 
2.8 TRANSPOSON MUTAGENESIS 
 
 
 Insertion of the trimethoprim cassette into pHYB-MTV was performed 
using the EZ::TNTM <DHFR-1> Insertion Kit (EPICENTRE, Madison, WI).  
pHYB-MTV (0.2 µg) was incubated with an equimolar amount of the EZ::TN 
<DHFR-1> transposon and 1 U EZ::TN transposase in a 10 µl reaction.  The 
mixture was incubated 2 hr at 37oC, and the reaction was terminated by addition 
of SDS to a final concentration of 0.1% and incubation for 10 min at 70oC.  One 
µl of the reaction was used to electroporate E. coli DH5α cells using a Bio-Rad 
Gene PulserTM (Bio-Rad Laboratories, Hercules, CA) (1.7 kV, 200 ohms and 25 
mF).  SOC medium was added immediately to the cells, transferred to a tube, and 
incubated for 1 hr at 37oC with shaking.  Clones with the insertion were selected 
on trimethoprim-containing plates (100 µg/ml).  Individual colonies were then re-
isolated on trimethoprim (100 µg/ml)/ampicillin (50 µg/ml)-containing plates to 





2.9.1 DNA fractionation 
 
 Cytoplasmic and nuclear DNA fractions were prepared from tissue culture 
cells after transfection or infection.  Cells were washed with 1X PBS and  counted 
using a hemocytometer.  For every 2 x 107 cells, 1.5 ml cold low-salt buffer 
(LSB) (10 mM sodium chloride (NaCl), 3 mM magnesium acetate, and 20 mM 
Tris-HCl [pH 7.4]) was added, and the cell pellet resuspended.  Lysis buffer (0.5 
ml) (5% sucrose and 1.2% Triton-X 100 in LSB) was added and mixed, and the 
nuclei were pelleted using an IEC Centra CL3R centrifuge at 700 x g for 10 min 
at 4oC.  The cytoplasmic fraction was removed, and EDTA was added to a final 
concentration of 25 mM.  The DNA from the cytoplasmic fraction was 
precipitated with ethanol after adjustment to 0.2 M NaCl followed by an 
incubation of 30 min at -20oC.  The DNA was centrifuged in an Avanti J-E 
centrifuge for 30 min at 12100 x g at 4oC, resuspended in 2 ml Solution IV (75 
mM NaCl, 25 mM EDTA, 20 mM Tris-HCl [pH 7.4], and 0.5% SDS) with 100 
µg/ml proteinase K, and incubated for 1 hr at 37oC.  To the remaining nuclear 
fraction, 5 ml Solution IV containing 100 µg/ml proteinase K was added.  The 
nuclear DNA was sheared six times by passage through a 25 gauge needle six 
times and incubated for 1 hr at 37oC.  Both fractions were extracted once with a 
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mixture of equilibrated phenol-chloroform (1:1; v/v) and precipitated with ethanol 
as previously described.  The DNA was centrifuged at 12100 x g for 30 min at 
4oC, washed with 70% ethanol, and resuspended in 2 ml of TE (10:0.1). 
 
2.9.2 RNA fractionation 
 
 
 The cytoplasmic and nuclear RNA fractions were obtained using the DNA 
fractionation protocol with modifications.  All solutions were treated with 0.1% 
diethyl pyrocarbonate (DEPC), and 8 µl/ml polyacryl carrier was added for each 
ethanol precipitation.  DEPC-treated Solution IV (2.5 ml) was added to both 
fractions, and 200 µg/ml proteinase K was added to the cytoplasmic fraction 
keeping the nuclear fraction at 100 µg/ml proteinase K.  After the ethanol 
precipitation, both fractions were resuspended in 300 µl TE (10:0.1), and the 
DNA contaminants were removed after RNA precipitation using 3 volumes of 4 
M sodium acetate (NaOAc) (pH 5.3).  The RNA from both fractions then was 
pelleted at 15000 x g for 30 min at 4oC and washed with DEPC-treated 70% 
ethanol.  The RNA was resuspended in DEPC-treated H20, and the concentration 








2.10 RNA PREPARTION 
 
 
 Total RNA was prepared from tissue culture cells by adding 1ml of RNA 
extraction buffer (4 M guanidine isothiocyanate, 25 mM sodium citrate, [pH 7.0], 
0.1 M 2-mercaptoethanol, 0.5% N-laurosarcosine, 50% water-saturated phenol to 
adjust to pH 7.0, and 0.2 M NaOAc [pH 4.0]) directly to a 35 mm culture plate 
containing approximately 2x106 cells.  One-fifth volume of chloroform was 
added, and the solution was mixed and the phases were separated in a Microfuge 
18 centrifuge at 15000 x g for 5 min at (25oC).  The upper phase was collected 
into another tube, three-fifths volume isopropanol was added and mixed, and then 
the solution was incubated for 20 min at 25oC.  The RNA was precipitated by 
centrifugation at 15000 x g for 30 min at 4oC.  The pellet was resuspended in 100 
µl of DEPC-treated TE (10:0.1).  The RNA was further precipitated with three 
volumes of 4 M NaOAc (pH 5.3) to remove DNA contaminants, and the mixture 
was incubated for 15 min at (25oC).  The mixture was centrifuged at 15000 x g for 
15 min at 4oC and washed with 70% DEPC-treated ethanol.  The RNA pellet was 
resuspended in 100 µl DEPC-treated H20, and the concentration was determined 












 Five-fold dilutions were performed on the DNA recovered from DNA 
fractionation of the transfections and infections, and PCR was performed to 
compare the DNA levels.  Five µl of each dilution was used in a 50 µl reaction 
using Taq polymerase (Invitrogen) and GFP primers using the protocol provided 
by Invitrogen.  The PCR conditions were:  denaturation at 94oC for 3 min, 25 
cycles of denaturation at 94oC for 1 min, annealing at 55oC for 1 min, and 
extension at 72oC for 1.5 min, and a final extension step at 72oC for 10 min in a 
PTC-100 programmable thermal controller (MJ Research, Inc., Watertown, MA.) 
 Colony PCR was performed on the mutagenized clones of pHYB-MTV to 
localize the integration site.  A bacterial clone was inoculated into 5 tubes each 
containing 5 µl H2O and used for colony PCR with 5 different primer pairs (C/D, 
E/F, G/H, I/J, and K/L) (Table 2.3) and Klentaq polymerase (AB Peptides, St. 
Louis, MO) in a 20 µl reaction.  The PCR conditions were:  denaturation at 94oC 
for 3 min, 30 cycles of denaturation at 94oC for 1 min, annealing at 55oC for 1 
min, and extension at 72oC for 1.5 min, and a final extension step at 72oC for 10 
min. 
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 MMTV fragments from pHYB-MTV were obtained by PCR for cloning 
into the p∆RL-BGH vector.  Ten ng pHYB-MTV was used with PfuTurbo 
(Stratagene, La Jolla, CA) and different primer pairs using the conditions 
provided by the manufacturer in a 50 µl reaction.  The PCR conditions were:  
denaturation at 94oC for 3 min, 30 cycles of denaturation at 94oC for 1 min, 
annealing at 55oC for 1.5 min, and extension at 72oC for 1.5 min. 
 
2.11.2 Reverse-transcriptase PCR (RT-PCR) 
 
 
 Ten µg of RNA from tissue culture cells was diluted with DEPC-treated 
H20 to a final volume of 41.5 µl.  The RNA then was treated with 3 U 
amplification-grade DNase I (Invitrogen) and 5 U RNase inhibitor (Invitrogen) 
for 1 hr at 37oC.  The DNase I was inactivated by addition of EDTA to a final 
concentration of 2.5 mM and incubation at 72oC for 15 min.  Five µg of the 
DNase I-treated RNA was further processed to make cDNA in a reverse 
transcriptase (RT) reaction.  The primer poly(dT17) and dNTPs were added to the 
RNA in final concentrations of 2.5 pmol/µl and 1 mM, respectively, boiled for 5 
min, and immediately placed on ice for 5 min.  The RNA was reverse transcribed 
using 400 U Moloney murine leukemia virus reverse transcriptase, 5 U RNase 
inhibitor, and 10 mM dithiothreitol (DTT) in a 50 µl reaction.  Two and a half µl 
of cDNA was used in each RT-PCR using specified primer pairs and polymerases 
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for each mRNA (Table 2.3).  Taq polymerase was used for PCR products less 
than 1 kb.  PCR conditions were:  denaturation at 94oC for 3 min, 50 cycles of 
denaturation at 94oC for 1 min, annealing at 55oC for 1 min, and extension at 
72oC for 1 min, and a final extension step at 72oC for 5 min in a PTC-100 
programmable thermal controller.  Expand Long Template polymerase (Roche, 
Indianapolis, IN) was used for PCR products larger than 1 kb.  PCR conditions 
were:  denaturation at 94oC for 2 min, 30 cycles of denaturation at 94oC for 20 
sec, annealing at 55oC for 30 sec, and extension at 68oC for 6 min, and a final 
extension step at 68oC for 8 min using the same thermocycler. 
 
2.12 FLUORESCENCE-ACTIVATED CELL SORTING (FACS) 
 
 
 Cells were harvested after infections or transfections and pelleted by 
centrifugation at 450 x g for 5 min at 4oC using an IEC Centra CL3R centrifuge.  
The cells were resuspended in 1 ml 1X PBS, and 300 µl of the cells were removed 
and pelleted in a Microfuge 18 centrifuge at 450 x g for 5 min at 25oC.  The cells 
were resuspended in 300 µl fresh 1X PBS, transferred to Falcon polysterene 
round-bottom tubes (Becton Dickenson, Franklin Lakes, NJ), and analyzed for 
GFP using a FACSCaliber flow cytometer and CELLQuest software.  Forward 
scatter and side scatter plots were used to determine the cell population to be 
selected for GFP analysis, and at least 10,000 cells were analyzed.  The 
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percentage of GFP-positive cells was then used to determine if DNA had been 
delivered from bacteria to eukaryotic cells or to normalize for DNA uptake in a 
transfection. 
 
2.13 REPORTER GENE ASSAYS 
 
 
 Luciferase assays were performed using the Dual-Luciferase Reporter 
Assay System (Promega) to quantitate Renilla luciferase and to normalize for 
DNA uptake with either firefly luciferase or GFP-positive cells.  Briefly, cells 
were harvested in 1X passive lysis buffer (Promega) and subjected to two freeze-
thaw cycles in a dry ice/ethanol bath.  The lysates were centrifuged for 5 min at 
15000 x g at 4oC to remove cellular debris, and the supernatant transferred to 
another tube.  The protein concentration was determined using the Bio-Rad 
Protein assay by comparison to a bovine serum albumin standard.  A total of 40 
µg or 20 µl was used to obtain luciferase readings using a Turner TD-20e 
luminometer (Turner Designs, Inc., Sunnyvale, CA) that was set to 0 delay and 10 
sec integrate.  Fifty µl of Luciferase Assay Reagent II was added to the sample, 
and the firefly luciferase activity was determined for the pGL2-Promoter (Table 
2.2) to normalize for DNA uptake.  The Renilla luciferase activity was determined 




2.14 IMMUNOBLOT ANALYSIS 
 
 
 Transfected cells were harvested in radioimmunoprecipitation assay 
(RIPA) buffer (50 mM Tris-HCl [pH 7.4], 150 mM NaCl, 1% Triton-X 100, 1% 
sodium deoxycholate, 0.1% SDS, 1 mM phenylmethylsulfonyl fluoride [PMSF], 
2 mM DTT, 100 µg/ml Leupeptin, 1 µg/ml Pepstatin A, and 40 µg/ml Aprotinin).  
Debris was removed by centrifugation at 13000 rpm for 5 min at 4oC, and the 
protein concentration was determined using the Bio-Rad Protein assay.  Fifty µg 
of sample was loaded onto an 8% to 10% Polyacrylamide Gel Electrophoresis 
(PAGE) gel containing 0.1% SDS and transferred onto a nitrocellulose 
membrane.  The membrane was then blocked with 5% milk in Tris-Buffered 
Saline Tween-20 (TBST) (20 mM Tris-HCl [pH 7.6], 137 mM NaCl, and 0.05% 
Tween-20) for 1 hr at 25oC with shaking.  The primary antibody was diluted in 
TBST containing 1% milk and incubated with the membrane for 1 hr at 25oC with 
shaking.  The membrane was washed 3 times for 5 min each in TBST with 
shaking, and the horseradish peroxidase antibody was then diluted in TBST 
containing 1% milk and incubated with the membrane for 45 min at 25oC with 
shaking.  The membrane was washed again 3 times for 5 min each with TBST.  
Western Lightning enhanced chemiluminescent reagent (Perkin Elmer, Wellesley, 
MA) was used to detect antibody binding. 
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2.15 SITE-DIRECTED MUTAGENESIS 
 
 
 Mutation of a specific site in a large plasmid was performed using a 
modified protocol of the Stratagene QuickChange Site-Directed Mutagenesis kit 
adapted by Wang and Wilkinson (241).  A pair of complementary 
oligonucleotides with the sense primer (5’- GTG CTT ATG ATA TTC CCG ATT 
GTG TTT CAA TGC CTT GCG AAG AGC C-3’) was synthesized to contain the 
mutations (in bold) with at least 10 bases of homology to the template plasmid on 
each end of the primers.  The PCR mixture contained 125 ng each 
oligonucleotide, 50 ng template, 5% DMSO, and 2.5 U PfuTurbo DNA 
polymerase (Stratagene).  The PCR conditions were:  denaturation at 95oC for 30 
sec, and 18 cycles of denaturation at 95oC for 30 sec, annealing at 60oC for 1 min, 
and extension at 68oC for 14 min in a PTC-100 programmable thermal controller.  
The DNA was digested with 40 U DpnI for 4 hours at 37oC to remove the original 









3.1 DEVELOPMENT OF A BACTERIAL DELIVERY SYSTEM 
 
3.1.1 Shigella infections  
 
 
 Gene therapy requires vector delivery to cells for subsequent expression of 
a therapeutic protein (170,209,249).  One potential delivery method utilizes 
vector-containing bacteria to target and invade cells and, once inside, bacterial 
lysis releases the bacterial cell contents, including the vector, into the eukaryotic 
cell.  Previous studies have shown that an asd mutant of Shigella, which requires 
the prokaryotic amino acid diaminopimelic acid (DAP), invades eukaryotic cells 
but lyses and delivers its contents within the cytoplasm due to the absence of DAP 
(207).  Delivery of a green fluorescent protein (GFP) to human epithelial cells 
using the asd mutant was previously demonstrated by S. Seliger (personal 
communication).  However, to use the MMTV trafficking ability to the mammary 
gland, the vector must be released into B and T cells.  Therefore, to determine if 
the Shigella asd mutant could deliver a vector to mouse or human B and T cells, a 
modified infection protocol was used for suspension cells. 
 Four B and T cell lines were assayed for susceptibility to Shigella asd 
infection, and GFP constructs with various promoters were tested for delivery 
(Table 3.1).  None of the cell lines examined showed significant GFP expression 
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with any of the GFP vectors (data not shown).  To verify functionality of the 
promoter, a Shigella asd mutant transformed with a GFP vector containing a T-
cell specific promoter from Type B leukemogenic virus (TBLV) was used to 
infect Jurkat T cells, and the percentages of cells expressing GFP were compared 
to results from a transient transfection using the same vector constructs.  GFP 
expression was observed at both 24 and 48 hr following infection, but relatively 
little expression (~0.1%) was observed at either time point (Fig. 3.1).  By 
comparison, the transient transfection showed about 5% expression in cells for 
both time points, a 50-fold increase in GFP expression relative to the infection.  
These results suggested low expression was due to the Shigella delivery method 















Table 3.1. Plasmids utilized in bacterial infections. 
Plasmid Characteristics 
pJZ466 Eukaryotic GFP expression vector 
containing an IRES-GFP 
pCD3GFP Eukaryotic GFP expression vector 
carrying the SV40 promoter 
pCMV-EGFP Eukaryotic GFP expression vector 
carrying the CMV promoter 
p19TLTR-EGFP Eukaryotic GFP expression vector 
carrying the TBLV LTR as the promoter 
pSS351 Eukaryotic GFP expression vector 
carrying the CMV promoter and lacO 
sites 
pSS356 yopE promoter region and first 49 codons 
fused to lacI 
pLR56 Prokaryotic vector that expresses invasin 
pHYB-MTV MMTV hybrid provirus in a pBR322 
derivative 
pIB29MEK Y. pseudotuberculosis virulence plasmid 
containing yopH, yopM, yopE, and yopK 


































Fig. 3.1. Expression of GFP in Jurkat T cells. 
Jurkat T cells were either transiently transfected with p19TLTR or 
infected with a Shigella asd mutant containing p19TLTR.  Cells were 
harvested at 24 or 48 hr, and the percentages of cells expressing GFP 








 Next we determined if there was a problem with vector delivery after 
bacterial infection.  To examine this possibility, transient transfections and 
bacterial infections both were performed on Jurkat T cells, and the cells were 
fractionated into cytoplasmic and nuclear DNA fractions.  PCR was performed on 
5-fold dilutions of each fraction, and the relative levels of DNA from the fractions 
were compared (Fig. 3.2).  A 25-fold increase in delivery efficiency was observed 
between the transient transfections and the bacterial infections for both the 
cytoplasmic and nuclear fractions.  These results revealed the inefficiency of the 















































Fig. 3.2. Semi-quantitative PCR analysis of vector localization in the 
cytoplasmic and nuclear fractions. 
 
(A) DNA from transiently transfected Jurkat T cells was subjected to 
5-fold serial dilutions beginning with 5 ml of a 1:125 dilution in lanes 
4 and 8.  (B) DNA from Jurkat T cells infected with the Shigella asd 
mutant transformed by p19TLTR was subjected to 5-fold serial 
dilutions.  Each set of dilutions was used for PCRs with GFP primers 







3.1.2 Yersinia infections  
 
 
 The type III secretion system (TTSS) of Yersinia allows secretion and 
translocation of proteins into the cytoplasm of eukaryotic cells through a pore 
created by the bacteria (41,42,124).  To utilize the TTSS as a gene therapy 
delivery method, a modified translocation system was constructed and used to 
transport a GFP vector into eukaryotic cells for expression.  Yersinia containing 
the pSS356 plasmid (Table 3.1) should produce a protein with a truncated YopE 
protein containing the secretion and translocation signals fused to the lac 
repressor (lacI) (Fig. 3.3).  The GFP vector used in the Yersinia experiments 
(pCMV-EGFP, Table 3.1) was constructed to contain lac operators that are bound 
by lac repressor, allowing this plasmid to be transported into the eukaryotic cell 
for expression during translocation of the YopE-LacI protein.  Other studies from 
Dr. Shelley Payne’s lab have shown delivery of GFP to human epithelial cells 















GFP can be 
expressed
LacI binds to lacO
on the reporter plasmid
YopE then pulls 
the plasmid into the




Fig. 3.3. Strategy for delivery of GFP plasmids to eukaryotic cells using the 
type III secretion system of Yersinia. 
 
The Yersinia contain a plasmid with a prokaryotic promoter that 
allows expression of a YopE-LacI fusion protein.  The LacI can bind 
to lacO sites located on GFP plasmids also present in the Yersinia.  
The YopE uses its secretion and translocation signals to move into the 
cytoplasm of the eukaryotic cell through a pore of the type III 
translocation sys tem.  The GFP plasmid also should move  into the 
cytoplasm due to LacI binding to the lacO. 
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 To determine if this system could deliver a GFP vector to lymphocytes so 
that the MMTV trafficking ability to the mammary gland could be utilized, 
modified infections were performed on a panel of three mouse and human B and 
T cell lines.  None of the cell lines showed detectable GFP expression.  
Unexpectedly, when a linear scale was used to set the analysis gate for the 
lymphocyte population, two different populations were observed (Fig. 3.4).  The 
circled population contained cells that were the normal population to be gated for 
analysis, while the other population showed cells with a different size and 
granularity than those of the normal population.  This other population most likely 
consists of dead or dying cells; however, these cells also might consist of living 
cells that are undergoing morphological changes due to the addition of the 
bacteria.  This other cell population for these cell lines was unusually high 
compared to other bacterial infection analyses, and these data suggested that the 


















































































Fig. 3.4. Analysis of the population of B and T cells after bacterial infection. 
Linear forward and side scatter plots are shown for (A) A20 B cells, 
(B) LBB.11 B cells, and (C) RLmale1 T cells.  For each, the first panel 
shows an infection by Yersinia, and the second panel shows an 
infection by Shigella harvested at 48 hr.  The viable cell population is 




 Since Dr. Payne’s lab had previously obtained GFP analysis results from 
Yersinia infection of HeLa cells and did not report cell toxicity, we repeated their 
analysis conditions.  The infection was assayed at 48 hr, and forward and side 
scatter FACS analysis was performed on both linear and log scales.  Most cell 
types are routinely analyzed on a linear scale as was previously performed on the 
HeLa cell infection.  After infection, the HeLa cells were lifting off the plate and, 
therefore, insufficient attached cells were available to harvest and analyze for the 
correct population or GFP expression; however, the unattached cells were still 
harvested for analysis.  The unattached HeLa cells appear to be a normal 
population that contains living cells (circled population) (Fig. 3.5A).  However, 
for the same unattached HeLa cells, the logarithmic plot distinguishes two distinct 
populations (Fig. 3.5B).  The circled population contains the live cells that should 
be analyzed, while the majority of the cells are located in another population 




































Fig. 3.5. Analysis of the population of HeLa cells after infection by Yersinia. 
(A) HeLa cells are shown using a linear forward and side scatter plot.  
(B) HeLa cells are shown using a logarithmic forward and side scatter 





 The experiment also was modified to use shorter bacterial incubation 
times that potentially would reduce cell death.  The HeLa cells were harvested at 
both 24 and 48 hr to determine if and when cell death was occurring, and the 
mock-infected cells were analyzed with and without cytochalasin D (CCD), 
which prevents bacterial uptake into the cell.  At both time points, the mock cell 
populations looked similar and appeared to be a normal population, suggesting 
that CCD does not affect the viability of HeLa cells (Fig. 3.6).  Twenty-four hr 
after Yersinia infection, the cell populations were starting to disperse, but a 
population could still be observed and analyzed (circled population).  However, 
48 hr after the addition of the Yersinia, a tight population is no longer seen, and 
the cells are quite dispersed.  These data and previous results suggested that 
Yersinia infection of eukaryotic cells causes cytotoxicity. 
 In addition to observing cell death, GFP expression also was analyzed.  
Little expression was observed, and the results were inconsistent when examined 
by gating on the normal population seen in the mock- infected cells (black circle) 
(Fig. 3.6).  This outcome was mostly likely due to the unusual population of cells 
after the addition of the bacteria.  GFP expression also was observed on the entire 
ungated population to determine the effect of autofluorescence from the dead or 
dying cells.  After 24 hr, when the cells still appeared as a normal population, no 
GFP expression was seen (Fig. 3.7).  These results suggested that the cells were 
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dying, and no delivery of the vector had taken place.  After 48 hr, when the cells 
were dispersed and later in the dying process, a peak separate from the mock peak 
appeared, which normally would indicate delivery of the GFP vector.  This peak 
also was seen in earlier studies, yet these data were not supported by the gated 
results.  Analysis of gated cells suggested that the peak was due to 
autofluorescence from the dead cells.  Since we were unable to prevent the cell 








































































Fig. 3.6. Analysis of the population of HeLa cells after infection by Yersinia at 
 different time points. 
 
HeLa cells are shown using a linear forward and side scatter plot after 
(A) 24 hr and (B) 48 hr.  The Yersinia used to infect the HeLa cells are 
indicated above the panels.  Mock- infected HeLa cells with and 
without CCD were used as a negative control for the cells and the 
drug.  The normal population of cells is indicated with a black circle.  
Plasmid pSS351 is the eukaryotic expression vector carrying CMV-
GFP and lacO sites, whereas pSS356 is the prokaryotic vector carrying 









































































































Fig. 3.7. Expression of GFP in HeLa cells after infection by Yersinia at 
different time points. 
 
HeLa cells are shown using a histogram plot after (A) 24 hr or (B) 48 
hr.  The Yersinia used for HeLa infection are indicated above the 




3.1.3 E. coli infections 
 
 
 The genetics of E. coli are widely known and can easily be manipulated 
(20,35).  Therefore, this system was used in combination with the TTSS of 
Yersinia to deliver vectors to eukaryotic cells.  To determine whether E. coli 
would kill eukaryotic cells, a preliminary infection of HeLa epithelial cells and 
A20 B cells was performed.  E. coli transformed with different plasmids as well 
as an invA plasmid that produces invasin needed for attachment to β1 integrins on 
cells (described in Table 3.1) were used for infection.  Both the HeLa cells and 
the A20 B cells infected with E. coli showed no observable increase in cell death 
when compared to the mock- infected cells, with the exception of the A20 B cells 
infected with the E. coli containing pHYB-MTV, an infectious MMTV provirus 
(Fig. 3.8).  However, the 10% cell death observed was 5-fold lower than that of 
the A20 B cells infected with Yersinia.  In addition, the HeLa cells were analyzed 
with propidium iodide, which is a fluorescent dye that is only incorporated into 
the DNA of dead or dying cells (215).  At 48 hr post infection, the amount of 
fluorescent dead cells was similar (~30%) between the mock-infected cells and 
the bacterially- infected cells (Fig. 3.9).  Together, these results suggest that E. coli 









































































Fig. 3.8. Analysis of the population of A20 cells and HeLa cells after infection 
by E. coli. 
 
A forward and side scatter plot is shown for (A) mock-infected cells, 
(B) DH5α/pHYB-MTV-infected cells, and (C) DH5α/pIB29MEK-
infected cells.  The first panel in each set shows A20 B cells, and the 
second panel shows HeLa epithelial cells.  The mock- infected cells 
were used as a negative control, and the normal population of cells is 
indicated with a black circle.  pHYB-MTV contains an infectious 
MMTV provirus, whereas pIB29MEK is a Yersinia virulence plasmid 













































Fig. 3.9. Propidium iodide analysis of HeLa cells after infection by E. coli. 
 
HeLa cells were either (A) mock- infected, (B) infected with 
DH5α/pHYB-MTV, or (C) infected with DH5α/pIB29MEK and 
harvested at 48 hr.  Each panel shows the infected HeLa cells treated 
with propidium iodide with the normal population of cells located in 
the lower rectangle.  Propidium iodide incorporation into dead cells is 
shown as a shift upward, and the percentages of these cells are 
indicated in the top right corner of the panel.  pHYB-MTV contains an 
infectious MMTV provirus, whereas pIB29MEK is a Yersinia 
virulence plasmid containing mutations in yopH, M, E, and K. 
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 Although E. coli did not kill the cells, it was unclear whether the bacteria 
attached to the cells using the invasin provided from Yersinia.  To determine if 
attachment occurred, the invA gene was integrated into the E. coli chromosome 
(DH5α/inva), and the bacteria were transformed with a prokaryotic GFP 
expression plasmid (pLR71, Table 3.1).  The DH5α/inva bacteria then were 
utilized for infections of HeLa epithelial cells and lymphocytes, and infections 
with E. coli carrying the GFP plasmid, but without invasin, were used as controls 
(DH5α/pLR71).  The cell lines used for infection expressed β1 integrins, to which 
the invasin could bind, on their surface (data not shown), so it was expected that 
cells would show an increase in fluorescence when the bacteria contained the 
invasin gene.  Surprisingly, with both the HeLa cells and the RLmale1 T cells, the 
same change in fluorescence was observed even after infection with the E. coli 
that did not contain the invasin gene (Fig. 3.10).  Despite this, approximately 10% 
of HeLa cells had attached bacteria, while 100% of RLmale1 cells showed 
bacterial attachment.  These results suggested that either the E. coli were able to 
attach to the cells by a means other than the invasin, or that non-specific binding 



























































Fig. 3.10. Attachment of fluorescent bacteria to human HeLa or mouse RLmale1 
cells after infection by E.coli. 
 
A histogram plot is shown for (A) mock- infected cells, (B) 
DH5α/pLR71-infected cells, and (C) DH5α/inva/pLR71-infected cells 
harvested at 48 hr.  The first panel in each set shows HeLa  epithelial 
cells, and the second panel shows RLmale1 T cells.  The mock-
infected and DH5α/pLR71-infected cells were used as negative 
controls.  Bacterial attachment to the eukaryotic cells is shown as a 
shift to the right of the peak of mock- infected cells. 
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 To determine the level of nonspecific binding, the bacteria and cells were 
centrifuged through a Histopaque gradient that pelleted the bacteria and allowed 
the eukaryotic cells to remain at the interphase.  For the RLmale1 T cells, the 
infection without the Histopaque was the same as reported earlier (compare Fig. 
3.10 and 3.11A).  When the infection was repeated using the Histopaque washing, 
some of the non-specific binding was detected, but the majority of the cells 
appeared to bind E. coli irrespective of the invasin (Fig. 3.11B).  To determine if 
another protein or mechanism was being used for attachment, the EL4b T cell 
line, which does not express β1 integrins, was used for the infection.  The results 
observed for EL4b cells without Histopaque washing were comparable to those 
observed for the RLmale1 cells, i.e., all the eukaryotic cells had attached bacteria 
(Fig. 3.12A).  To remove unattached bacteria, the infection was repeated with 
Histopaque washing.  Surprisingly, although 50% of the cells had non-specifically 
bound bacteria, half of the eukaryotic cells showed bacterial attachment that could 
not be attributed to the invasin (Fig. 3.12B).  These results demonstrate that E. 
coli attach to eukaryotic cells through at least two mechanisms.  Further 






























































Fig. 3.11. Attachment of fluorescent bacteria to RLmale1 mouse T cells after 
infection by E. coli measured by different washing techniques.  
 
A histogram plot is shown for the infected RLmale1 cells washed with 
(A) phosphate-buffered saline or (B) Histopaque and harvested at 48 
hr.  The E. coli used to infect the RLmale1 cells are indicated above 
the panels.  The mock- infected and DH5α/pLR71-infected cells were 
used as negative controls.  Fluorescent bacteria attached to the cells are 


























































Fig. 3.12. Attachment of fluorescent bacteria to EL4b mouse T cells after 
infection by E. coli measured by different washing techniques. 
 
A histogram plot is shown for the infected EL4b cells washed with (A) 
phosphate-buffered saline or (B) Histopaque and harvested after 48 hr.  
The E. coli used to infect the EL4b cells are indicated above the 
panels.  The mock- infected and DH5α/pLR71-infected cells were used 
as negative controls.  Fluorescent bacteria attached to the cells are 
shown as a shift to the right of the peak of mock- infected cells. 
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3.2 CONSTRUCTION AND CHARACTERIZATION OF A GFP-
 TAGGED MMTV 
 
 
3.2.1 Analysis of GFP expression from the tagged MMTVs 
 
 
 MMTV is a retrovirus that causes mammary gland carcinomas following 
infection and amplification in B and T cells (6,26,56,70).  Since MMTV first 
infects these immune cells, lymphocyte trafficking or homing must occur before 
infection of the mammary gland.  Although much is known about lymphocyte 
homing to specific tissues (117,230,247), the mechanism of MMTV transmission 
from gut-associated lymphocytes to the mammary gland is not well understood.  
Use of MMTV as a gene therapy vector requires additional details of virus-cell 
interactions. 
 To examine MMTV trafficking from infected lymphocytes to the 
mammary gland, a GFP-tagged MMTV was constructed as described in the 
Materials and Methods.  Briefly, an IRES-GFP was engineered 3’ to the highly 
expressed env gene after duplication of the sequence shared by both env and sag 
(refer to Materials and Methods).  Duplication of these shared sequences would 
allow GFP translation from the env mRNA without truncating the essential sag 
mRNA.  The GFP-tagged MMTV clones initially were tested for GFP expression 
by transient trans fection of XC fibroblast cells (Fig. 3.13).  The positive control 
plasmid containing the IRES-GFP used for cloning (pJZ466, Table 3.2) showed 
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that approximately 17% of the XC cells expressed GFP.  Transfection of two 
GFP-tagged MMTV plasmid isolates, pHYB-GFP.1 and pHYB-GFP.8, showed 
approximately 3% and 4.5% of XC cells expressing GFP, respectively.  These 
results suggested that the GFP-tagged MMTV clones expressed GFP, but at 3- to 
5-fold lower levels than the GFP expression plasmid used as a positive control. 
 
 





pJZ466 Eukaryotic GFP expression vector 
containing an IRES-GFP 
pHYB-GFP.1 One clone of the pHYB-MTV derivative 
containing an IRES-GFP 3’ to the env 
gene 
pHYB-GFP.8 Another clone of the pHYB-MTV 
derivative containing an IRES-GFP 3’ to 
the env gene 
pMMTV-GFP Eukaryotic GFP expression vector 
carrying the C3H MMTV LTR as the 
promoter 
pHYB-GFPmSA pHYB-GFP.1 derivative containing a 
mutated splice acceptor preceding the 
IRES-GFP 
pHYB-GFPmSA.bs pHYB-GFPmSA derivative containing a 
branch site and polypyrimidine tract 





























Fig. 3.13. Expression of GFP in XC cells from the tagged-MMTVs. 
XC fibroblast cells were transiently transfected with either pJZ466 or 
GFP-tagged MMTVs.  Cells were harvested at 48 hr, and the 
percentages of cells expressing GFP are shown as means of triplicate 








 The MMTV env mRNA is transcribed from the hormone- inducible U3 
promoter (146,227).  Since GFP also is expressed from the env mRNA, we 
determined if GFP expression could be induced by the glucocorticoid, 
dexamethasone (Dex).  XC cells were transiently transfected, and 10-6 M Dex was 
added to the cells for 24 hr prior to fluorescence assays.  The plasmid pMMTV-
GFP (Table 3.2), which uses the MMTV promoter, was used as a positive control 
and had a 3-fold increase in GFP expression in the presence of Dex (Fig. 3.14).  
The clones pHYB-GFP.1 and pHYB-GFP.8 also had a 3-fold and 6.5-fold 
increase in GFP expression, respectively, upon addition of Dex, whereas a non-
inducible plasmid, pJZ466 (Table 3.2), showed no increase in GFP expression 
after Dex induction (data not shown).  These results demonstrated that GFP 
expression is Dex inducible and most likely originates from the hormone-




































Fig. 3.14. Expression of GFP from the tagged-MMTVs after Dex induction in 
XC cells. 
 
XC fibroblast cells were transiently transfected with either pMMTV-
GFP, which expresses GFP under the control of the MMTV LTR, or 
GFP-tagged MMTV mutants.  Dex (10-6 M) was added to the cells 
after 24 hr, and the cells were harvested at 48 hr.  The percentages of 
cells expressing GFP are shown as means of triplicate transfections 






3.2.2 Expression of viral transcripts from GFP-tagged MMTVs 
 
 
 Since both env and sag are required for a productive MMTV infection, 
functional proteins also will be required for use of MMTV as a gene therapy 
vector.  To verify that the duplication of the env and sag sequence as well as the 
insertion of an IRES-GFP had not disrupted expression of either of these genes, 
RT-PCR was performed on total RNA harvested from transiently transfected XC 
cells to detect viral mRNAs.  Primers designed to detect gag, env, and sag 
mRNAs, as well as primers to detect the IRES within the env mRNA, were used 
in the RT-PCR analysis (Fig. 3.15).  The positive control pHYB-MTV as well as 
the GFP-tagged MMTV clones all produce gag and env mRNAs (Fig. 3.16).  
Surprisingly, only pHYB-MTV showed a product for the sag mRNA, suggesting 
that the pHYB-GFP clones do not make a sag transcript.  Since wild type MMTV 
does not contain an IRES-GFP, pHYB-MTV does not show a band for the env-
IRES mRNA.  The expected amplification product for the env-IRES mRNA was 
approximately 2 kb, yet the bands seen with both GFP-tagged MMTV clones are 
approximately 900 bp.  The 900 bp band was isolated and sequenced.  Sequence 
analysis verified that the 900 bp band was a PCR product from the env and IRES 
primers used, but suggested that alternative splicing might be occurring. 
 To further analyze the transcripts detected, the splice donor (SD) and 
splice acceptor (SA) sites were examined for all the mRNAs.  A 2 kb env-IRES 
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transcript from the U3 promoter might be expected after removal of the gag-pol 
intron (Fig. 3.15).  The smaller PCR product observed suggested that a doubly-
spliced mRNA was being produced (Fig. 3.16D). The sag mRNA transcribed 
from wild-type MMTV is expressed from an intergenic env promoter (59) and 
uses SD 7315 in env and a SA site that is located approximately 70 bp before the 
3’ LTR.  During the construction of the GFP-tagged MMTVs, SA 8467 located 
prior to the IRES-GFP was maintained and an engineered SA was placed between 
IRES-GFP and the 3’ LTR.  Since sag transcripts were not detected using the 
GFP-tagged MMTV clones, the RT-PCR results suggest that the original SA is 








































Fig. 3.15. Diagram of the splice donor and splice acceptors in the GFP-tagged 
MMTV. 
 
The proteins of the GFP-tagged MMTV are shown as horizontal lines 
above the provirus, and the splice donors and splice acceptors are 
indicated by vertical lines within the provirus.  The viral transcripts are 
shown by the dotted lines below the provirus, and the primers used for 























































Fig. 3.16. Detection of viral transcripts from XC cells transiently transfected 
with GFP-tagged MMTVs. 
 
XC fibroblast cells were transiently transfected with either pHYB-
MTV or GFP-tagged MMTVs, and total RNA was harvested 48 hr  
post transfection.  cDNA was prepared, and RT-PCR performed for 
(A) gag mRNA, (B) env mRNA, (C) sag mRNA, and (D) IRES 
mRNA using the indicated primers.  Arrows show the locations of the 
expected products for each primer pair listed.  The gapdh mRNA was 




3.2.3 Construction and characterization of a GFP-tagged MMTV with a 
 mutated splice acceptor 
 
 
 The splicing machinery of a eukaryotic cell frequently utilizes the first SA 
located after a SD site (36).  The GFP-tagged MMTV clones also appear to use 
this common strategy since no sag mRNA is being produced.  Therefore, to 
construct a GFP-tagged MMTV with the ability to produce sag mRNA, the SA 
site located before the duplicated sequence (SA 8467) was mutated using a 
modified protocol for the Stratagene QuickChange Site-Directed Mutagenesis kit.  
The resulting clone, pHYB-GFPmSA (Table 3.2), was transiently transfected into 
XC cells to determine if GFP was expressed (Fig. 3.17).  The positive control 
plasmid pJZ466 showed 3.2% GFP expression, while pHYB-GFPmSA only 
showed 0.2% GFP expression.  Although the expression leve l varied from 
previous results, probably due to different transfection efficiencies, the GFP 
expression from pHYB-GFPmSA is considerably lower than that from the 
previous pHYB-GFP construct.  This is not surprising since pHYB-GFP had both 
a doubly-spliced IRES-GFP mRNA and a singly spliced mRNA from the env 
intergenic promoter in addition to the env-IRES mRNA from the U3 promoter 
(Fig. 3.15).  However, in pHYB-GFPmSA, two of the mRNAs used to translate 





























Fig. 3.17. Expression of GFP in XC cells from the tagged-MMTV containing a 
mutated splice acceptor. 
 
XC fibroblast cells were transiently transfected with either pJZ466 or a 
GFP-tagged MMTV containing a mutated splice acceptor.  Cells were 
harvested at 48 hr, and the percentages of cells expressing GFP are 







 Total RNA also was harvested from transiently transfected XC cells to 
determine if viral mRNAs could be detected (Fig. 3.18).  Similar to results with 
pHYB-GFP, both gag and env mRNAs were detectable from the pHYB-GFPmSA 
transfections.  The env-IRES mRNA was not detected after mutation of the SA at 
position 8467.  However, the previously detected 900 bp PCR product also was 
not observed (Fig. 3.18C).  The difficulty in detecting the env-IRES mRNA was 
probably due to the PCR conditions and the length of the product.  Since the 
pHYB-GFPmSA construct does not produce a sag mRNA, there appear to be 

































































Fig. 3.18. Detection of viral transcripts from XC cells transiently transfected 
with GFP-tagged MMTV containing a mutated splice acceptor. 
 
XC fibroblast cells were transiently transfected with either pHYB-
MTV or pHYB-GFPmSA containing a mutated splice acceptor, and 
total RNA was harvested 48 hr  post transfection.  cDNA was prepared, 
and RT-PCR performed for (A) gag mRNA, (B) env mRNA, (C) sag 
mRNA, and (D) IRES mRNA using the indicated primers.  Arrows 
show the locations of the expected products for each primer pair listed.  
The gapdh mRNA was used as a control, and all PCRs were analyzed 




3.2.4 Construction and characterization of a GFP-tagged MMTV 
 containing splicing regulatory sequences 
 
 
 Previous studies on splicing have shown that sequences other than the SD 
and SA sites are important for recognition by the splicing machinery of the cell 
(87,153).  These sequences include a polypyrimidine tract as well as a branch site, 
which is the adenine attacked for splicing to occur (Fig. 3.19).  The engineered 
SA site in pHYB-GFPmSA did not contain any of these additional sequences and 
may have prevented sag mRNA production.  Therefore the sag mRNA 
polypyrimidine tract and branch site sequences were inserted before the 
engineered SA site in pHYB-GFPmSA as follows.  Two complementary 
oligonucleotides were synthesized that contained a branch site, a polypyrimidine 
tract, a SA site, and flanking restriction enzyme sites.  These oligonucleotides 
were annealed and phosphorylated, and the clone pHYB-GFPmSA.bs was created 
by substitution of this more complete splice site for that engineered into pHYB-
GFPmSA (Table 3.2).  To determine if sag mRNA was expressed from this 
construct, XC cells were transiently transfected and total RNA was harvested for 
RT-PCR analysis (Fig. 3.20).  Unexpectedly, pHYB-GFPmSA.bs did not produce 
a sag mRNA, although env mRNA was detectable.  These results suggested that 
either the cellular splicing machinery was not functioning as expected, or the 








Branch Site Polypyrimidine Tract
3’Splice Acceptor
11 to >40 nts
 
 
Fig. 3.19. RNA sequences important for recognition by the splicing machinery. 
The RNA sequences that are important for recognition by the splicing 
machinery are shown as consensus sequences from mammalian cells.  
The 5’ splice donor, the branch site, the polypyrimidine tract, and the 
3’ splice acceptor are all indicated.  The branch site is located from 11 
to greater than 40 nucleotides before the 3’ splice acceptor, and it is 
the adenine (A) from this branch site that is recognized by the splicing 
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Fig. 3.20. Detection of viral transcripts from XC cells transiently transfected 
with GFP-tagged MMTV containing splicing regulatory sequences. 
 
XC fibroblast cells were transiently transfected with either pHYB-
MTV or GFP-tagged MMTV containing splicing regulatory 
sequences, and total RNA was harvested at 48 hr post transfection.  
cDNA was prepared, and RT-PCR was performed using the  indicated 
primers.  Arrows show the locations of the expected products for each 
primer pair listed.  The gapdh mRNA was used as a control, and all 





3.2.5 Detection of the capsid protein from the GFP-tagged MMTV mutants 
 
 
 The RT-PCR analysis is necessary to detect sag mRNA since Sag 
antibody (Ab) is not available (27,150,181).  To determine if viral structural 
proteins are expressed from the GFP-tagged MMTV proviruses, immunoblot 
analysis was performed on lysates harvested from transiently transfected XC cells 
(Fig. 3.21).  Polyclonal or monoclonal MMTV CA-specific Ab was used to detect 
CA from pHYB-MTV transfected cells as a positive control.  Using the 
polyclonal Ab, the expected CA precursor Pr77 protein was observed (lane 2).  A 
slightly slower migrating, non-specific band appears in all lanes, and this non-
specific band was eliminated with monoclonal CA-specific Ab.  Surprisingly, 
none of the GFP-tagged MMTV clones expresses CA protein.  These results 
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Fig. 3.21. Immunoblot analysis of CA expression from GFP-tagged MMTV 
mutants. 
 
XC fibroblast cells were transiently transfected with either pHYB-
MTV or the GFP-tagged MMTV mutants, and protein lysates were 
harvested at 48 hr post transfection.  The proteins were separated using 
a 10% PAGE gel containing SDS, and (A) a polyclonal MMTV CA-
specific antibody or (B) a monoclonal MMTV CA-specific antibody 
was used to detect the capsid precursor Pr77.  The arrows indicate the 
expected products.  Actin was used as a control for the amount of 
protein loaded.  
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3.2.6 Detection of unspliced mRNA in the cytoplasm of a GFP-tagged 
 MMTV mutant 
 
 
 Spliced mRNAs are processed in the nucleus and exported to the 
cytoplasm via pathways mediated by different proteins, e.g., Crm1 or TAP 
(156,184,222).  Synthesis of retroviral capsid proteins requires unspliced gag 
mRNA export from the nucleus for translation.   Retroviruses use different 
strategies depending upon their complexity; however, the reported sequences 
needed for export are all located at the 3’ end of the virus near the env gene 
(61,83,88,229).  Since GFP-tagged MMTV clones all had mutations at the 3’ end 
of the virus, it is possible that nuclear RNA export sequences also were altered. 
 The previous RT-PCR results were analyzed using total RNA.  To 
determine whether the gag transcript could be exported to the cytoplasm, RNA 
was isolated from cytoplasmic and nuclear fractions of transiently transfected XC 
cells and subjected to RT-PCR analysis (Fig. 3.22).  As expected, gag mRNA 
from pHYB-MTV was detected in both the nuclear and cytoplasmic fractions, 
although the cytoplasmic RNA level was much lower than the nuclear fraction.  
Surprisingly, the cytoplasmic fraction of pHYB-GFPmSA had undetectable gag 
mRNA, yet the gag transcript was observed in the nuclear fraction.  The env 
transcript was detected in both cytoplasmic and nuclear fractions from pHYB-
MTV and pHYB-GFPmSA transfected cells.  These results suggest that CA 
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protein is not produced from the mutant provirus because the gag mRNA cannot 
be exported to the cytoplasm.  Thus, the tagging of MMTV with GFP may have 
























































Fig. 3.22. Cytoplasmic and nuclear mRNA fractionation of XC cells transiently 
transfected with pHYB-MTV and GFP-tagged MMTV with a mutated 
splice acceptor.  
 
XC fibroblast cells were transiently transfected with either pHYB-
MTV or the GFP-tagged MMTV with a mutated splice acceptor, and 
cytoplasmic and nuclear RNA fractions were harvested at 48 hr post 
transfection.  cDNA was prepared, and RT-PCR performed for (A) 
gag mRNA and (B) env mRNA using the indicated primers.  Arrows 
show the locations of the expected products for each primer pair listed.  
The gapdh mRNA was used as a control, and all PCRs were analyzed 
by agarose gel electrophoresis. 
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3.3 DEVELOPMENT AND CHARACTERIZATION OF TRANSPOSON-
 MUTAGENIZED MMTVS 
 
 
3.3.1  Production of transposon-mutagenized MMTVs 
 
 All retroviruses contain several important cis-acting elements 
(22,108,152,218), yet most elements have not been mapped in the MMTV 
provirus.  The previous results suggested that the GFP-tagged provirus sustained 
alterations that prevented nuclear export of gag-pol mRNA.  Development of a 
working vector for gene therapy requires identification of essential viral elements 
and, therefore, mutagenesis of pHYB-MTV was performed.  The mutagenized 
pHYB-MTV was useful for localization of cis-acting elements but also for 
determining which genes and their products are necessary for MMTV trafficking 
to the mammary gland. 
 The pHYB-MTV plasmid was mutagenized in vitro using the DHFR-1 
(trimethoprim) cassette as a transposon.  The Epicentre EZ::TN transposon kit 
allowed for the transposon to be inserted randomly into either the MMTV 
provirus or the vector backbone, usually with one hit per plasmid.  After 
electroporation into DH5α bacterial cells, individual colonies were screened by 
colony PCR with a panel of five primer pairs to identify the location of transposon 
insertion (Fig. 3.23).  Screening continued until a pool of mutants for each region 
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was obtained.  Several mutants from each region then were selected and analyzed 




C3H LTR 1+ Gag 620-
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Fig. 3.23. Location of primers and trimethoprim cassettes within the 
mutagenized MMTV provirus. 
 
The five primer pairs used for the colony PCR are shown above the 
MMTV provirus with arrows.  The primer pairs divide the provirus 
into seven regions indicated by the different colors:  yellow-5’ LTR, 
white-gag, gray-gag/pro, blue-pol, pink- pol/env, green-env, and 
orange-3’ LTR/sag.  The pool of mutants obtained is shown in the box 

























































Fig. 3.24. Locations of transposon insertions in MMTV mutants. 
 
The MMTV proteins are shown as colored boxes above the MMTV 
provirus.  The asterisks, ampersands, and number signs indicate the 
location of transposon insertions that were localized by sequencing.  
Mutants were labeled according to the location of the insertion and the 






3.3.2 Development and characterization of stably integrated transposon-
 mutagenized MMTVs 
 
 
 Previous experiments in the lab have shown that XC cells stably 
transfected with pHYB-MTV induce MMTV infection when injected into mice 
(155,253).  To determine which viral genes are necessary for trafficking to the 
mammary gland, transposon mutants from different proviral regions were selected 
and stably transfected into XC cells.  Retention of the stably integrated provirus 
and the transposon were verified by RT-PCR and immunoblot analysis. 
 Total RNA was harvested from the XC cells stably transfected with the 
mutated proviruses, and RT-PCR was performed to identify gag, env, and sag 
transcripts.  Each mutant expressed bands of the same size as those produced by 
wild-type pHYB-MTV, unless the insertion occurred within that gene (Fig. 3.25 
and 3.26).  For example, the mutants gag 2 and gag 3 have the ca. 890 bp 
trimethoprim cassette inserted in the region between the primers used to detect 
gag mRNA and, therefore, due to the non-processivity of the polymerase used for 
the RT-PCR, a band is not produced.  However, mutants gag 131 and gag 189 
have an insertion outside the 230+ and gag620- primer pair, but within the gag 
gene and, thus, a band is observed for the gag mRNA (Fig 3.26A).  Interestingly, 
some of the stably transfected XC cell lines did not show the RT-PCR expression 
pattern predicted from transposon location.  For example, the mutant gag 28 does 
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not show a band for gag mRNA as predicted, but neither is env mRNA detected 
(Fig. 3.25B, lane 5) due to the transposon insertion just 5’ to the env splice donor.  
The mutant env 95 also showed an unusual expression pattern for the sag mRNA 
(Fig. 3.26C, lane 6).  A doublet was observed at the expected size of 723 bp, and 
another ~400 bp band was detected with this mutant, but not with other mutant-
transfected cells or the positive control.  The transposon insertion for mutant env 
95 is not located near the SD or SA for sag, but it is possible that the insertion 
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Fig. 3.25. Detection of mutant MMTV constructs in stably transfected XC cells. 
XC fibroblast cells were stably transfected with transposon-
mutagenized MMTVs.  Total RNA was harvested, and cDNA was 
prepared for RT-PCR analysis of (A) gag mRNA, (B) env mRNA, and 
(C) sag mRNA using the indicated primers.  The gapdh mRNA was 
used as a control, and PCRs were analyzed by agarose gel 
electrophoresis.  Arrows show the location of the expected products 
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Fig. 3.26. Detection of mutant MMTV constructs in stably transfected XC cells. 
XC fibroblast cells were stably transfected with transposon-
mutagenized MMTVs.  Total RNA was harvested, and cDNA was 
prepared for RT-PCR analysis of (A) gag mRNA, (B) env mRNA, and 
(C) sag mRNA using the indicated primers.  Arrows show the location 
of the expected products for the primer pairs listed.  The gapdh mRNA 







 Cell lysates also were harvested from the stably transfected mutant cell 
lines, and the monoclonal ΜΜΤV CA-specific Ab was used to detect CA protein 
using pHYB-MTV as a positive control (Fig. 3.27).  As anticipated, the pol, env, 
sag, and LTR mutants all produced the capsid precursor Pr77, whereas none of 
the six gag mutants were able to produce any protein since the gene was disrupted 
by the transposon cassette.  However, the protein levels of mutants env 12, env 95, 
and sag 8 were all significantly lower than wild type levels, despite the 
localization of each mutation outside the gag gene.  The verification of mRNA 
and protein expression from these XC transfectants provides valuable reagents to 
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Fig. 3.27. Immunoblot analysis of CA expression from XC cells stably 
transfected with various MMTV constructs.  
 
Protein lysates were harvested from XC cells stably transfected with 
wild-type or mutant MMTV proviruses and were separated on 10% 
PAGE gels containing SDS.  Capsid precursors Pr110 and Pr77 were 
detected using an MMTV CA-specific antibody.  The arrows indicate 
the expected products.  Actin was used as a protein loading control. 
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3.3.3 Identification of MMTV genes necessary for trafficking to the 
 mammary gland  
 
 
 After initial analysis of the stably transfected cell lines, mutants from each 
gene region were selected and injected into BALB/c weanling mice using the 
mutant 5’ LTR 152 as a positive control.  This mutant reverts to wild type viral 
RNA after DNA integration and transcription because an insertion in the 5’ U3 
region of the LTR is not transcribed by RNA polymerase II.  The mice were 
analyzed two months after injection to monitor the percentage of CD4+Vβ14+ T 
cells, a measure of MMTV infection due to Sag-mediated deletion.  The 
uninjected controls showed a normal percentage of CD4+Vβ14+ T cells, whereas 
the mutant 5’ LTR 152 showed T-cell deletion that was statistically significant 
from the uninjected controls (Fig. 3.28).  None of the transposon mutants deleted 
CD4+Vβ14+ T cells, which indicated that an active infection did not occur with 
any of the mutants.  These results suggest that all of the viral proteins are needed 





































































Fig. 3.28. CD4+Vβ14+ T cell deletion analysis from injected BALB/c mice. 
XC cells stably transfected with the transposon-mutagenized MMTVs 
were injected into BALB/c mice and compared to uninjected mice.  
The mutant 5’ LTR 152 was used as a positive control since wild type 
levels of viral proteins were detected despite the presence of a 
transposon in the 5’ LTR (see text).  The percentage of CD4+Vβ14+ T 
cells was determined using the FACS as described in the Materials and 
Methods.  The values are shown as means of four injections with 
standard deviations.  An asterisk indicates values that are significantly 






 The sag mutants theoretically lack Sag production, although this is 
difficult to verify because there are no available Sag-specific antibodies.  
Furthermore, these mutants would not delete the Vβ14+ T cells since Sag protein 
mediates this deletion.  Therefore, MMTV transmission to the mammary gland 
was monitored by RT-PCR.  Mammary gland RNA was harvested from each 
injected mouse (four mice for each construct) and analyzed for gag and sag 
mRNAs.  The uninjected controls expressed neither C3H-specific gag or sag 
mRNA, as expected, and 75% of the positive controls injected with mutant 5’ 
LTR 152 expressed both gag and sag mRNA (Fig. 3.29).  However, RT-PCR 
analysis was unable to detect infection in mammary glands of one of the 5’ LTR 
152-injected mice, despite deletion of Vβ14+ T cells in this animal (Fig. 3.28).  
This result suggests that either the virus was not transmitted to the mammary 
gland or that the expression levels were too low to detect by RT-PCR.  A gag 
mRNA product was not observed for any of the other mutant- injected mice, and 
most of these mice also showed no sag mRNA product.  However, the sag 7 and 
sag 165 mutants each had one injected mouse that showed a sag mRNA product 
(Fig. 3.29 asterisks) even though a gag mRNA product was not detected for either 
mutant.  It appears likely that the RT-PCR primers are able to detect sag mRNA 
levels more efficiently than the gag mRNA, which would explain detection of a 
sag mRNA product in the absence of gag.  These results suggested that sag 
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mutants infect mammary glands with approximately 25% efficiency.  These 
results also support previous findings from our lab, which showed that MMTV 
mutants expressing nonfunctional sag genes sporadically infect mammary glands 
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Fig. 3.29. Analysis of viral transcripts from mammary glands of injected 
BALB/c mice. 
 
Stably transfected XC cells containing the transposon-mutagenized 
MMTVs were injected into BALB/c mice.  Uninjected mice were used 
as negative controls and mice injected with the mutant 5’ LTR 152 
were used as positive controls.  Total RNA was harvested from 
mammary gland tissue, and cDNA was prepared for RT-PCR analysis  
of (A) gag mRNA and (B) sag mRNA using the indicated primers.  
The arrows to the right of the gel show the products observed for each 
transcript.  The gapdh mRNA was used as a control, and all PCRs 









 Previous results indicated that mutations in the 3’ portion of pHYB-MTV 
compromise the expression of CA.  To determine specific insertion sites that 
prevent CA expression, transient transfections of XC cells were performed using 
transposon mutants from the pol, env, sag, and the 3’ LTR regions.  Most of the 
mutants were able to express the CA precursor Pr77 at wild type levels; however, 
three of the env mutants did not express Pr77 at all (Fig. 3.30).  Results from the 
transient transfections of some mutants did not correspond to the results from the 
stably transfected mutants.  The mutants sag 8 and env 95 had reduced levels of 
Pr77 when stably integrated, whereas Pr77 expression appears to give wild-type 
levels after a transient transfection.  The mutant env 149 had the exact opposite 
result since wild-type levels of Pr77 were observed in stable transfection assays, 
but no expression was detected in a transient transfection.  Potentially, such 
different results could be due to: (i) loss of proviral expression from specific 
MMTV integration sites or cell clones in the infected population or (ii) the 
increased sensitivity of stable, compared to transient, assays due to the 
inefficiency of the latter. 
 RT-PCR analysis was performed on total RNA from the transient 
transfections to determine whether absence of CA expression was due to lack of 
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gag mRNA production.  All transposon mutants expressed gag mRNA in 
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Fig. 3.30. Immunoblot analysis of CA expression from XC cells transiently 
transfected with transposon-mutagenized MMTVs.  
 
XC fibroblast cells were transiently transfected with transposon-
mutagenized MMTVs, and protein lysates were harvested.  The 
proteins were separated using 10% PAGE gels containing SDS and 
detected using MMTV CA-specific antibody 48 hr post transfection.  
The arrows to the right of the gels indicate the expected products.  
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Fig. 3.31. Expression of gag mRNA in XC cells transiently transfected with 
transposon-mutagenized MMTVs. 
 
XC fibroblast cells were transiently transfected with transposon-
mutagenized MMTVs.  Total RNA was harvested, and cDNA was 
prepared for RT-PCR analysis of gag mRNA using the indicated 
primers.  Arrows show the location of the expected products for the 
primer pairs listed.  The gapdh mRNA was used as a control, and all 







 Earlier experiments with the GFP-tagged MMTV showed that the gag 
mRNA, while expressed, was not exported to the cytoplasm.  Therefore, the three 
env mutants that failed to produce Pr77 in transient transfections were subjected 
to RNA fractionation to determine the location of the gag mRNA.  The results 
show that none of the mutants exported gag mRNA into the cytoplasm at wild-
type levels, although low levels could be detected (Fig. 3.32).  These results 
suggest that the env mutants are compromised for CA expression due to reduced 
export of the gag transcript.  Two of the mutants, env 12 and env 148, are located 
approximately 200 bp apart at the 5’ end of env, whereas mutant env 149 is 
located at the 3’ end of env directly upstream of the SA for sag near the 3’ LTR.  
This result suggested that there are two different elements or a bipartite element 
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Fig. 3.32. Nuclear and cytoplasmic mRNA fractionation of XC cells transiently 
 transfected with transposon-mutagenized MMTVs. 
 
XC fibroblast cells were transiently transfected with three different env 
mutants, and cytoplasmic and nuclear RNA fractions were harvested 
48 hr post transfection.  cDNA was prepared, and RT-PCRs were 
performed using the indicated primers.  The arrows show the location 
of the expected products for the primer pairs listed.  The gapdh mRNA 










3.4 IDENTIFICATION OF CIS- OR TRANS-ACTING ELEMENTS 
 LOCATED IN THE MMTV PROVIRUS 
 
 
3.4.1 Construction of a CTE-dependent reporter vector to characterize 
 MMTV mRNA export 
 
 
 Retroviruses have different methods to export unspliced RNA to the 
cytoplasm depending on the complexity of the virus.  Simple retroviruses, such as 
MPMV, depend on a CTE found in unspliced mRNAs as well as host factors that 
bind to the CTE for export of unspliced mRNAs to the cytoplasm (46,83,252).  
Complex retroviruses, such as HIV-1 and HTLV-1, encode proteins that bind to 
RNA elements located in unspliced or partially spliced mRNAs for cytoplasmic 
export (45,46,88).  MMTV is classified as a simple retrovirus.  Therefore, to 
determine whether MMTV contains a CTE, a CTE-dependent reporter gene was 
constructed. 
 The strategy used to construct the CTE-dependent reporter gene (Fig. 
3.33) also has been described in the Materials and Methods.  The Renilla 
luciferase reporter gene (Rluc) was utilized for the high sensitivity of the assay.  
Briefly, the chimeric intron from the vector pRL-TK was removed, and the SV40 
late polyA signal was replaced with the bovine growth hormone (BGH) polyA 
signal to create p∆RL-BGH.  p∆RL-BGH makes an unspliced Rluc mRNA, which 
is inefficiently exported into the cytoplasm unless a CTE is provided.  To 
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determine CTE activity, MMTV fragments then were cloned into the NotI site 
using the MPMV CTE as a positive control.  The MMTV fragments tested were 
derived from the 3’ end of MMTV, and they encompass (i) the sites of all three 
env mutants, (ii) the two 5’ env mutants, (iii) the one 3’ env mutant, or (iv) the 3’ 
MMTV LTR (Fig. 3.34).  CTE activity is dependent upon orientation 



























Fig. 3.33. Strategy to construct a CTE-dependent reporter gene. 
 
A CTE-dependent luciferase vector was constructed using (A) the 
Renilla luciferase reporter vector pRL-TK.  pRL-TK contains the RLuc 
reporter gene driven by the HSV TK promoter, a chimeric intron 
separating the gene from the promoter, an SV40 late polyA signal, and 
an ampicillin resistance gene.  To create the CTE-dependent luciferase 
vector, p∆RL-BGH (B), the chimeric intron was removed and the 
SV40 polyA signal was replaced with the BGH polyA signal.  MMTV 




















Fig. 3.34. Diagram of MMTV fragments used for assays of CTE activity. 
The MMTV proteins are shown by colored boxes labeled with the 
protein above the MMTV provirus.  The asterisks indicate the location 
of the transposon insertion for each env mutant unable to export 
unspliced mRNA to the cytoplasm.  The plasmid pHYB-MTV was 
amplified by PCR with multiple primer sets to generate different sized 
MMTV fragments (black lines) for cloning into the p∆RL-BGH vector 





 To determine which, if any, MMTV fragments contained a CTE, the 
newly constructed plasmids then were transiently transfected into XC cells.  XC 
cells were used since they are able to express MMTV proteins, and CTE activity 
should be detectable in these cells.  Cell lysates were harvested after 48 hr, and a 
luciferase assay was performed after normalization of Renilla luciferase (RLuc) 
activity for the percentage of cells positive for the co-transfected pEGFP-C1 (Fig. 
3.35).  The removal of the intron from the luciferase vector resulted in ca. 95-fold 
reduction in the relative RLuc activity.  Addition of the MPMV CTE in the 
forward orientation showed a statistically significant increase over the 
background leve l of p∆RL-BGH; however, the increase was slightly less than 2-
fold.  The MPMV CTE in the reverse orientation had ~40% lower RLuc activity 
than the p∆RL-BGH vector.  None of the MMTV fragments in the forward 
orientation showed an increase in RLuc activity over the p∆RL-BGH levels, but 
2F and 6F had luciferase levels similar to p∆RL-BGH.  MMTV fragments in the 
reverse orientation demonstrated 4- to 10-fold decreases in luciferase activity.  
These results suggested that the level of expression using the MPMV CTE (F), the 
positive control, was too low in XC cells for sensitive detection of CTE function.  
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Fig. 3.35. Activity of various MMTV fragments for mRNA export in XC cells. 
Luciferase reporter gene constructs were tested in XC cells.  Renilla 
luciferase activity is given in light units/100 µg of protein normalized 
for DNA uptake as measured by co-transfection with the pEGFP-C1 
plasmid.  RLuc activity is reported relative to that of pRL-BGH, 
assigned a value of 100, and the relative RLuc activities are shown as 
means of triplicate assays with standard deviations.  The positive 
control MPMV CTE forward orientation (F), the negative control 
MPMV CTE reverse orientation (R), and the MMTV fragments were 
compared to the activity of the p∆RL-BGH vector.  An asterisk 
indicates values that are significantly different from the p∆RL-BGH 




 Higher activity of the MPMV CTE has been reported in monkey and 
human cell lines (256).  Therefore, 293T human kidney epithelial cells were 
selected for tests of CTE function because they also allow MMTV Gag 
production and, therefore, must have export of unspliced viral RNA.  The 293T 
cells were transiently transfected, harvested, and assayed as previously described 
for the XC cells (Fig. 3.36).  As expected, the removal of the intron from the 
luciferase vector resulted in ca. 110-fold decrease in RLuc activity.  However, in 
293T cells, the addition of the MPMV CTE in the forward orientation 
demonstrated ca. 3.5-fold increase in RLuc activity.  This statistically significant 
increase is similar to the level reported with other CTE-dependent reporter vectors 
(164,256).  The MMTV fragments in the forward orientation again showed no 
increase in RLuc activity over levels observed with p∆RL-BGH.  All fragments, 
including the MPMV CTE, in the reverse orientation showed a decrease in 
activity from p∆RL-BGH levels as previously seen in the XC cells.  This 
experiment also was repeated in Jurkat human T cells and A20 mouse B cells, 
which are able to express MMTV Gag proteins, with similar results (data not 
shown).  Τhe MPMV CTE system, while inefficient in human cells, clearly 
showed a significant difference over background compared to results from rat 
(XC) or mouse (A20) cells, and none of the MMTV fragments in the forward 
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orientation had increased RLuc activity over background p∆RL-BGH levels.  
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Fig. 3.36. Activity of various MMTV fragments for mRNA export in 293T cells. 
Renilla luciferase activity is reported as described in Fig. 3.35.  An 
asterisk indicates values that are significantly different from the p∆RL-





3.4.2 Detection of novel MMTV mRNAs 
 
 MMTV requires export of unspliced and partially spliced mRNAs to the 
cytoplasm, so in the absence of a CTE, the virus must use an alternative mRNA 
export pathway.  The human endogenous retroviruses type K (HERV-K) are 
members of the betaretroviruses, which include MMTV, and HERV-K proviruses 
recently have been shown to produce a doubly spliced mRNA encoding an RNA 
export protein, Rec (130,131,134). MMTV produces Gag, Pol, Env, and Sag 
proteins from their corresponding mRNAs (92,105,155), and except for the 
unspliced gag-pol mRNA, all other known mRNAs are singly spliced (Fig. 3.37).  
Therefore to detect novel MMTV mRNAs, RT-PCR was performed on total RNA 
harvested from XC cells stably transfected with pHYB-MTV.  Because all 
MMTV strains should require mRNA export, Jurkat cells stably transfected with 
the MMTV strain TBLV also were used for RT-PCR.  MMTV and TBLV are 
98% identical with the differences occurring only in the LTRs.  Since the rest of 
the proviruses are identical, novel mRNAs detected in MMTV should also be 
detected in TBLV.  The primer pairs C3H 230+/C3H LTR 548- and C3H 
230+/C3H LTR 408- are at opposite ends of the provirus and were used to detect 
novel spliced mRNAs.  The primer C3H LTR 408- was used to detect mRNAs in 
TBLV because the primer C3H LTR 548- is located in the negative regulatory 
elements, a region deleted from the TBLV LTRs (10,32,50).  As expected, both 
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stable cell lines expressed both env and sag mRNAs (Fig. 3.38).  However, 
another strong band was detected between these mRNAs (thick arrow).  The 
novel band from XC and Jurkat stably transfected cells was isolated, and 
sequence analysis verified that this prominent new band was derived from a 
















































* Trimethoprimtransposon  
Fig. 3.37. Diagram of the known and newly identified MMTV mRNAs. 
The MMTV provirus is shown with the LTRs as green boxes and the 
proteins as blue rectangles.  MMTV promoters are represented by pink 
ovals.  The mRNA transcripts expressed by MMTV are shown below 
the provirus as dashed lines.  Splice donors (SD) and splice acceptors 
(SA) are indicated by black lines, and introns are shown as dotted lines 
with a “V” shape.  The location of the trimethoprim insertion for each 
labeled mutant is represented by a dark green asterisk.  Primers used to 
detect novel mRNAs are indicated above the gag-pol mRNA [Adapted 
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Fig. 3.38. Detection of novel viral transcripts in XC and Jurkat stable cell lines. 
Total RNA was harvested from (A) XC fibroblast cells and (B) Jurkat 
T cells stably transfected with pHYB-MTV and pTBLV, respectively, 
at 48 hr post Dex induction.  cDNA was prepared, and RT-PCR was 
performed using the indicated primers.  Arrows show the location of 
the transcripts for each primer pair listed.  The gapdh mRNA was used 







 The sequence of the novel 1500 bp RT-PCR product then was translated 
into an open reading frame of 301 amino acids.  This putative protein contained 
the Env leader peptide, or signal sequence, 162 amino acids from gp52 (SU), and 
41 amino acids from gp36 (TM) (Fig. 3.39).  Predicted protein motifs found using 
Motif Scan and ExPASy proteomics tools showed common motifs such as 
glycosylation, myristoylation, amidation, and protein kinase C phosphorylation 
sites.  Interestingly, this putative product also contained an NLS and an NES, 
which closely resemble sequences from Rev-related proteins (Figs. 3.39 and 
3.40), as well as an arginine-rich motif (ARM), which is an RNA-binding domain 
found in the Rev-related proteins (174).  These results suggest that MMTV 
contains a trans-acting protein used to export unspliced and partially spliced 
mRNAs to the cytoplasm.  This putative protein was named Rem for regulator of 
































PKC: Protein Kinase C
NLS: Nuclear Localization Signal
ARM: Arginine-rich Motif






* Trimethoprim transposon  
Fig. 3.39. Predicted motifs of the putative MMTV-encoded protein Rem. 
The putative protein Rem is shown as an amino acid sequence.  The 
Env leader peptide is indicated by blue letters, the SU sequence is 
indicated by red letters, and the TM sequence is indicated by black 
letters.  The exons are shown as lines above the amino acid sequence, 
and the predicted motifs are labeled below the sequence and indicated 
by horizontal arrows.  The location of the trimethoprim insertion for 























Fig. 3.40. Comparison of the NLS and NES sequences of Rev-related proteins. 
 
(A) The potential NLS of MMTV Rem is compared to Rev and other 
Rev- like proteins.  The arginine-rich sequence is represented by purple 
arginines (R).  (B) The potential NES of MMTV Rem is compared to 
Rev and other Rev-like proteins.  The leucine-rich sequence is 









 Complex retroviruses produce trans-acting proteins, such as Rev, which 
bind to viral RNAs and a cellular export factor, such as Crm1 (88,174).  Two of 
the three env mutants that were unable to transport unspliced mRNA to the 
cytoplasm had trimethoprim cassette insertions, one in the Env leader sequence 
and one in SU, in the Rem open reading frame.  To determine if MMTV 
expresses a trans-acting factor, complementation experiments were performed 
(see Fig. 3.41 for strategy).  Briefly, cells stably transfected with the env mutant 
only allowed transport of completely spliced mRNAs to the cytoplasm and, 
therefore, unspliced or partially spliced mRNAs can not be detected in the 
cytoplasm.  If MMTV expresses a trans-acting RNA export factor, then transient 
transfections of pHYB-MTV into the env mutant stable cells should allow export 
of the unspliced or partially spliced mRNAs into the cytoplasm if the env mutant 
transcripts contain an RRE-like element.  XC/env mutant stable cells were 
transiently transfected with pHYB-MTV.  Similarly, XC cells stably transfected 
with pHYB-MTV were transiently transfected with the env mutant plasmids, 
which also should allow export of unspliced or partially spliced mRNAs.  RNA 
was isolated from cytoplasmic and nuclear fractions of these cells as well as 
untransfected cells and subjected to RT-PCR analysis (Fig. 3.42).  Primers in pol 
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and the trimethoprim cassette were used to detect only the mutant unspliced 
mRNA.  As expected, the unspliced mRNA was detectable in the nuclear fraction 
of both untransfected and transfected mutant env 12 and 148 stable cells, but not 
in the untransfected cytoplasmic fraction of the mutant env 12 and 148 stable 
cells.  However, when pHYB-MTV was transfected into XC cells stably 
transfected with mutant env 148, or the mutant env 148 plasmid was transfected 
into XC cells stably transfected with pHYB-MTV, unspliced mRNA was 
detectable in cytoplasmic fractions (purple asterisks). 
 The recovery of the unspliced mRNA was only observed with the mutant 
env 148 and not the mutant env 12.  One possible explanation is that the insertion 
in the mutant env 12 disrupted both a cis-acting element in the RNA and the Rem 
open reading frame.  Disruption of the RNA element would prevent 
complementation even in the presence of the trans-acting protein.  The sag 
mRNA was used as a control for export to the cytoplasm, because this RNA is 
completely spliced and able to be exported by normal mechanisms.  As expected, 
the sag transcript was detected in the cytoplasmic fraction as well as the nuclear 
fraction for all transfected samples.  These results indicate that MMTV expresses 
a trans-acting factor that functions in export of unspliced or partially spliced 




















Fig. 3.41. Strategy for the complementation of the env mutant stable cell lines 
with the wild-type MMTV plasmid. 
 
(A) The cytoplasmic and nuclear fractions of mRNA transcripts from 
the env mutant stable cell line are shown.  All transcripts are indicated 
by a straight line flanked by a cap (m7G) and a polyA with some 
containing introns shown as lines in a “V” shape and the trimethoprim 
cassette indicated as a green rectangle.  All transcripts are expressed in 
the nucleus, but only the completely spliced mRNAs are exported.  
The unspliced or partially spliced mRNAs are not exported to the 
cytoplasm indicated by the red X.  (B) The possible cytoplasmic and 
nuclear fractions of mRNA transcripts from the env mutant stable cell 
line and the transiently transfected pHYB-MTV are shown.  The 
potential MMTV trans-acting factor is indicated by a gray rectangle 
















































































































Fig. 3.42. Nuclear and cytoplasmic mRNA fractionation of transiently 
transfected XC stable cell lines.  
 
XC cells stably transfected with either pHYB-MTV (HM) or env 
mutants (12 or 148) were transiently transfected respectively with the 
env mutant plasmids or pHYB-MTV, and cytoplasmic and nuclear 
RNA fractions were harvested at 48 hr post transfection.  cDNA was 
prepared, and RT-PCR performed for (A) gag-pol-trim mRNA or (B) 
sag mRNA using the indicated primers.  Arrows show the location of 
the expected products for each primer pair listed, and the purple 
asterisks indicate complementation occurring.  The gapdh mRNA was 











4.1 DEVELOPMENT OF A BACTERIAL SYSTEM FOR GENE 
 DELIVERY TO MAMMALIAN CELLS 
 
 
 Gene therapy requires both targeting of specific cells and efficient delivery 
and expression of genes to these cells (96,197,240,249,259).  Most gene therapy 
vectors accomplish at least one of the requirements; however, an ideal vector 
would be able to achieve all requirements.  Retroviral vectors are able to integrate 
into the host cell genome allowing stable and sustained expression of the 
delivered gene, yet many retroviruses infect a broad range of host cells instead of 
targeting specific cells (114,116,165).  MMTV infects lymphoid cells in the 
GALT after translocation through M cells, which then deliver the virus to 
mammary epithelial cells for subsequent infection and replication 
(56,72,142,180).  The targeting of mammary gland epithelial cells for infection 
and ability to integrate into the chromosome make MMTV an ideal vector for 
breast cancer gene therapy, yet MMTV infection of human cells appears to be 
inefficient.  Therefore a specific and efficient system for the delivery of MMTV 
vectors to the M cells and GALT is needed. 
 Bacterial delivery systems have been shown to deliver DNA to eukaryotic 
cells, and many of the bacterial systems will target M cells and the GALT in vivo 
(245,246).  The combination of viral and bacterial vectors would create one gene 
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therapy system that consists of (i) bacteria containing the MMTV-based vector 
that traffic to M cells and deliver the provirus to lymphoid cells and (ii) an 
MMTV provirus capable of trafficking from lymphocytes to mammary epithelial 
cells where expression of the delivered gene can occur. 
 
4.1.1 Delivery by Shigella to lymphoid cells is inefficient 
 
 
 Bacterial delivery of DNA to eukaryotic cells is usually accomplished 
through attenuated bacteria that escape from the phagocytic vacuole and lyse to 
release the DNA into the cytoplasm of the host.  Shigella require escape from a 
vacuole for replication, and several attenuated vectors that lyse in eukaryotic cells 
have been developed (43,160,161,245,246).  Previous studies have shown that a 
Shigella asd mutant, which requires the prokaryotic amino acid DAP, invades 
eukaryotic cells but will lyse within the cytoplasm due to the absence of DAP.  
This asd mutant also was shown to deliver both β-galactosidase and GFP to baby 
hamster kidney cells and human epithelial cells, respectively (207)(S. Seliger, 
personal communication).  However, DNA delivery to lymphoid cells is 
necessary for trafficking of the MMTV provirus to the mammary gland. 
 Human and mouse lymphoid cells were infected with several Shigella asd 
mutants containing GFP vectors driven by various promoters.  Delivery of the 
GFP vectors to lymphoid cells was not observed since significant GFP expression 
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with any of the vectors was not detected.  Comparisons of GFP expression in 
human Jurkat T cells between a transient transfection and bacterial infection 
indicated that the transient transfection was 50-fold more efficient than the 
bacterial delivery method (Fig. 3.1).  PCR analysis of the cytoplasmic and nuclear 
DNA fractions from both the transient transfection and bacterial infection also 
confirmed that delivery of GFP vectors from the Shigella asd mutant was 
inefficient when compared to transient transfection methods such as Superfect. 
 The differences between the previous results and the results shown here 
may be due to use of either adherent or suspension cells in the assay.  Adherent 
epithelial cells, which were used successfully for gene delivery, were grown in a 
monolayer that allowed each cell to contact the bacteria added.  However, 
lymphoid cells were grown in suspension and required a modified infection 
protocol involving the centrifugation of the bacteria onto the cells in a conical 
tube.  This modification may have resulted in two layers, with the bacteria 
overlaying the lymphoid cell layer.  If this is the case, only those cells at the top 
of the layer will contact the bacteria and decrease the efficiency of delivery.  
Attempts to alter the bacterial infection and increase the efficiency of delivery 
were unsuccessful. 
 In vivo delivery of GFP by the Shigella asd mutant to B and T cells in the 
GALT also was performed, but expression of GFP in these lymphoid cells was 
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not observed.  Instead, GFP expression was detected in the M cells and, therefore, 
lysis of the Shigella asd mutant apparently occurred prematurely in these cells (S. 
Seliger, personal communication).  These results showed the inefficiency of the 
Shigella asd mutant as a delivery system to lymphoid cells in the GALT and 
prompted a change to an alternative system. 
 
4.1.2 Gene delivery by Yersinia causes toxicity to eukaryotic cells 
 
 
 Most bacterial delivery systems require lysis of the bacteria for delivery of 
a gene to the cytoplasm of a host cell; however, previous results using a Shigella 
asd mutant have indicated that lysis occurs too early for DNA delivery to 
lymphoid cells in the GALT.  Therefore, a bacterial system that did not require 
lysis for delivery was developed using the Yersinia TTSS.  Yersinia replicate 
extracellularly in the GALT, and the TTSS allows the bacteria to evade the 
immune system by binding to immune cells and translocating proteins, or Yops, 
into the cytoplasm of the host cell.   
 The TTSS usually delivers proteins to the cytoplasm of eukaryotic cells, 
but the delivery system for gene therapy requires DNA delivery to the nucleus.  
Only the Yop secretion and translocation signals are needed to translocate other 
proteins into mammalian cells and, therefore, it was predicted that a single protein 
could bind DNA and allow translocation and delivery of both the protein and 
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DNA into the cytoplasm of a host cell (Fig. 3.3).  A fusion protein containing the 
secretion and translocation signals of the YopE protein and the lac repressor (lacI) 
was constructed in addition to a GFP vector containing lac operators to which lacI 
could bind.  Both were transformed into a Yersinia multiple Yop mutant (MYM) 
for use in delivery assays.  Delivery of GFP to human epithelial cells using this 
method has been shown by Dr. Shelley Payne’s lab (personal communication). 
 Mouse and human lymphoid cells were infected with the Yersinia MYM 
delivery system, yet no detectable GFP expression was observed.  Surprisingly, 
the addition of Yersinia to these eukaryotic cells caused an unusually high amount 
of cell death compared to other bacterial infections analyzed after 48 hr.  Cell 
toxicity was not reported for previous experiments using the fusion protein 
containing adenylate cyclase; however, Yersinia were removed from the cultured 
cells after only two hr, and the cells then were harvested for cAMP levels 
(19,98,211).  The short incubation of the Yersinia with the eukaryotic cells may 
not have detected toxic effects.  Previous results of GFP delivery to human 
epithelial cells also did not demonstrate cell toxicity (personal communication), 
although our results using this assay resulted in detachment of the epithelial cells, 
indicative of toxicity.  FACS analysis of the epithelial cells at different times after 
infection with Yersinia indicated that toxicity started after 24 hr and continued 
through 48 hr when compared to mock-infected cells.  GFP expression from these 
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Yersinia- infected epithelial cells also was not observed after gating on the normal 
population seen in the mock- infected cells.  However, a peak appeared when the 
entire population, including the dispersed and dying cells, was analyzed, 
suggesting autofluorescence from dead cells (Fig. 3.7B). 
 Together, it appears that Yersinia infection of cultured eukaryotic cells, 
both adherent and suspension cultures, causes cell toxicity.  Such results are not 
unexpected from wild-type Yersinia since the Yop proteins translocated into the 
cytoplasm of host cells exert their effects on cellular pathways, including those 
leading to apoptosis.  YopE, YopH and YopO have all been shown to have 
cytotoxic effects on cultured epithelial cells (42,82,192,193) and, therefore, the 
Yersinia strain utilized in these infections was the MYM strain, which contains 
mutations in yopH, E, K, O, and M.  After the development of the Yersinia MYM 
strain, a new protein YopT was identified that also has a cytotoxic effect on 
epithelial cells (42,98).  This protein is expressed from the Yersinia MYM strain 
and explains the cytotoxic effects observed in our experiments.  The effect of 
YopT on lymphoid cells has not been reported, although the cytotoxicity detected 
in the MYM infections of lymphoid cells indicates the same effect as on the 
epithelial cells.  Deletion of YopT from the MYM strain was not performed since 
YopT was identified recently, and it is possible that other unidentified Yersinia 
proteins also cause eukaryotic cell death.  Thus, the relatively uncharacterized 
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genetic background of Yersinia prompted use of a more defined genetic system 
for bacterial gene delivery. 
 
4.1.3 E. coli carrying invA are unable to specifically target lymphoid cells 
 
 
 The Yersinia delivery system appeared to cause cell toxicity.  Wild type E. 
coli is not invasive, but the genome is well characterized and can easily be 
manipulated.  Therefore, a delivery system was developed using E. coli 
containing the Yersinia TTSS.  The invasin gene (invA) from Yersinia 
enterocolitica also was expressed in E. coli to allow attachment to mammalian 
cells expressing β1 integrins (16,21,100,101).  Since lymphoid cells express β1 
integrins (8,171,248,258), E. coli carrying the invA and TTSS plasmids should 
target the lymphoid cells in the Peyer’s patches and deliver DNA into their 
cytoplasm.  The plasmid encoding the TTSS, pIB29MEK, contains mutations in 
yopH and yopE, but not yopO or yopT which are all known to cause cell toxicity.  
Thus infections of eukaryotic cells with E. coli containing pIB29MEK and 
another plasmid known to not cause cytotoxicity, pHYB-MTV, were performed. 
 FACS analysis of an epithelial cell line and a B cell line indicated that E. 
coli containing the Yersinia TTSS did not cause cell toxicity after 48 hr.  It is 
possible that YopO and YopT were not expressed in sufficient quantities to have 
an effect on cells or, alternatively, a protein expressed from the Yersinia 
 177 
chromosome is needed for the regulation of these proteins.  Although eukaryotic 
cell lysis could be prevented using a different bacterial system, it appears that E. 
coli were unable to attach to the eukaryotic cells using the invasin provided from 
Yersinia.  Lack of cell attachment would prevent translocation of the Yops into 
the cytoplasm of the host cell and, therefore, no cell toxicity would be observed. 
 To assess attachment, E. coli containing both the invasin gene and a 
prokaryotic GFP plasmid together with control E. coli that did not contain the 
invasin gene were utilized in infections of eukaryotic cells known to express β1 
integrins.  Only E. coli with the invasin gene should bind these cells and display 
fluorescence due to the GFP.  E. coli without invasin should be unable to bind 
specifically, and the eukaryotic cells then would have the same fluorescence as 
mock-infected cells.  Unexpectedly, eukaryotic cells infected with E. coli that did 
not contain invasin showed the same fluorescent shift as eukaryotic cells infected 
with E. coli containing invasin.  These results suggested that either non-specific 
binding between the E. coli and the eukaryotic cells had occurred or that the E. 
coli bind to such cells by a means other than invasin. 
 Non-specific binding might occur if the eukaryotic cells were not washed 
properly during the infection.  The T-cell line is a suspension cell line, and 
removal of bacteria requires centrifugation.  However, this centrifugation also 
may pellet the E. coli onto the cells and increase non-specific binding.  Since the 
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fibroblast cell line is adherent, most of the non-specific binding should be washed 
away.  The different washing procedures for each cell line may explain our results 
indicating that 100% of T cells had bacteria attached whereas only 10% of the 
fibroblast cells had attached bacteria in the absence of invasin.  To remove any 
non-specific binding after infection, the infected eukaryotic cells were centrifuged 
through a Histopaque gradient, which pellets the unattached E. coli but leaves the 
cells and any attached E. coli at the interphase.  Comparisons between the 
Histopaque washing and the previous method of washing indicated that non-
specific binding had occurred, yet the majority of the cells retained E. coli 
regardless of invasin expression.  These results suggested that E. coli binds to 
eukaryotic cells independent of the invasin.  EL4b T cells do not express β1 
integrins and, therefore, E. coli should not bind these cells if binding requires 
invasin.  Using the Histopaque method, half the EL4b cells still had attached E. 
coli.  These results suggest that E. coli attach to eukaryotic cells by an 
undetermined mechanism.  Since bacterial delivery needs to target cells 
specifically, the E. coli system must be further modified. 
 
4.2 DEVELOPMENT OF MMTV AS A GENE THERAPY VECTOR 
 
 Our original goal was the development of a bacterial vector that would 
specifically deliver an MMTV-based plasmid carrying a therapeutic gene 
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specifically to lymphocytes in the gut-associated tissues of mice.  This MMTV 
plasmid then would allow vector amplification in lymphocytes, which would 
traffic to the mammary epithelium.  Therefore, we attempted the development of a 
minimal plasmid which would accomplish this objective. 
 
4.2.1 GFP-tagged MMTV clones reveal a novel viral function 
 
 After MMTV infection of B and T cells in the GALT, these cells traffic to 
the mammary gland, where dividing mammary epithelial cells are infected during 
puberty (56,72,142,180).  However, little is known about MMTV targeting to the 
mammary gland.  Development of MMTV as a gene therapy vector requires 
detection of infected cells and their movement.  GFP has been utilized in many 
trafficking studies due to the simplicity of detecting this protein by microscopy.  
Therefore, GFP was used to tag the MMTV provirus. 
 Since the MMTV env gene is highly expressed, an IRES-GFP cassette was 
inserted 3’ to the env gene.  This strategy allows both a higher expression level for 
GFP and expression of an intact Env protein because the IRES enables GFP to be 
expressed independently from the Env protein.  Moreover, the intact Env protein 
ensures that MMTV replication will occur normally since an Env-GFP fusion 
protein might unintentionally affect virus-cell interactions.  However, the MMTV 
env gene overlaps the sag gene, which required duplication of the shared 
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sequence to allow full- length Sag expression.  FACS analysis of different GFP-
tagged MMTV clones indicated that GFP was expressed, although at reduced 
levels compared to the GFP-expression vector.  Since GFP expression also was 
inducible by glucocorticoids, our results suggested that GFP was expressed from 
the env mRNA, which is transcribed from the inducible U3 promoter.  Thus, GFP 
could be used to tag MMTV-infected cells. 
 
4.2.2 GFP-tagged MMTV clones fail to express a sag transcript 
 
 To determine if insertion of the IRES-GFP sequence altered MMTV 
transcription, RT-PCR analysis of transfected cells was performed.  GFP-tagged 
MMTV clones expressed both gag and env mRNAs.  However, none of the clones 
produced a sag transcript from the intragenic env promoter (Fig. 3.16), and each 
produced an env-IRES transcript that was not the expected size.  When the shared 
sequence between env and sag genes was duplicated, the original splice acceptor 
for the sag gene (SA 8467) was located 5’ to the duplicated sequence and the 
IRES-GFP cassette.  To preserve sag mRNA splicing, an engineered splice 
acceptor was inserted upstream of the 3’ LTR (Fig. 3.15).  Cellular splicing 
machinery prefers the most 5’ splice acceptor and also completely removes all 
introns from mRNA, consistent with our observations with the GFP-tagged 
MMTV clones (36,121,153).  The unexpected product detected for the env-IRES 
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transcript corresponds to a doubly spliced transcript that uses both splice donor 
and splice acceptors, and the inability to detect sag mRNA most likely resulted 
from use of the first splice acceptor at position 8467 instead of the engineered 
second splice acceptor. 
 The original splice acceptor located 5’ to the duplicated sequence was 
mutated to facilitate correct splicing of the sag gene, and FACS analysis showed 
that GFP expression was maintained.  However, RT-PCR analysis again indicated 
that sag mRNA was not expressed despite gag and env mRNA production.  
Sequences other than the splice donor and splice acceptor have been shown to be 
important for recognition by the splicing machinery of the cell, including a 
polypyrimidine tract and a branch site (Fig. 3.19) (87,153).  Lack of such 
sequences proximal to the engineered splice acceptor may explain failure to 
produce sag transcripts.  The probable polypyrimidine tract and branch site for the 
sag mRNA were reinserted 5’ to the engineered splice acceptor, yet a sag 
transcript remained undetectable by RT-PCR analysis. 
 Retroviruses require expression of both spliced and unspliced mRNAs for 
replication, yet cellular machinery usually splices cellular mRNAs to completion 
before export to the cytoplasm.  To allow expression of both forms of mRNAs, 
retroviruses must regulate the splicing events that take place in the nucleus 
(46,134,229).  Retroviruses are known to use suboptimal splice sites, including 
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the polypyrimidine tract and branch site, which ensures that unspliced or 
incompletely spliced mRNAs are available for export (174,213,224).  Wild-type 
MMTV maintains suboptimal splice sites to produce a sag transcript and, 
therefore, the GFP-tagged MMTV clone that includes the polypyrimidine tract 
and branch site also should produce sag mRNA.  However, the actual 
polypyrimidine tract and branch site have not yet been identified for the MMTV 
sag mRNA, so it is possible that the sequences required for this transcript were 
inadvertently omitted.  Exon sequences also regulate splicing, and both positive 
and negative elements have been identified in retroviruses (4,5,174,214).  The 
expression of sag mRNA from wild-type MMTV suggests that negative splicing 
elements are not a factor.  However, the duplication of the MMTV env/sag 
junction in addition to the insertion of the IRES-GFP cassette may have shifted a 
splicing enhancer element to a location that is too distant to act upon the sag 
splice acceptor, thus preventing correct expression. 
 
4.2.3 GFP-tagged MMTV clones lack Gag protein production due to a 
 defect in viral RNA export 
 
 
 Cells transfected with the GFP-tagged MMTV clones also were tested for 
the capsid protein and its precursors.  Immunoblot analys is indicated that the 
capsid protein was not expressed since the precursor Pr77 was not detected.  
These results were surprising since all the changes to the MMTV provirus were 
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located in the env gene, whereas the capsid protein is expressed from the gag 
gene.  However, as stated previously, retroviruses require expression of unspliced 
or partially spliced mRNAs and subsequent export to the cytoplasm for 
expression of the Gag, Pro, and Pol proteins.  This RNA export mechanism differs 
depending on the complexity of the retrovirus, although elements controlling 
export are located in the 3’ end of the virus, including the env gene (45,46,229).  
To determine if the changes to the env gene interfered in the ability to export 
unspliced transcripts to the cytoplasm, cytoplasmic and nuclear RNA fractions 
from cells transfected with the GFP-tagged MMTV clones were subjected to RT-
PCR analysis.  The results showed that the GFP-tagged MMTV clones were 
unable to export unspliced mRNA to the cytoplasm, although such RNAs were 
detectable in the nuclear fraction.  These experiments suggest that the viral 
mechanism used to export unspliced mRNA was impeded by the changes in the 
env gene, which led to the inability to express capsid protein. 
 
4.2.4 Transposon mutagenesis of the MMTV provirus  
 
 
 Retroviruses contain cis-acting elements such as a packaging and RNA 
export signals, while complex retroviruses also contain trans-acting factors that 
modulate export (174,186,229).  At least one element required for RNA export 
was altered in the GFP-tagged MMTV provirus.  Therefore, identification of such 
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sequences is necessary for development of an MMTV-based gene therapy vector.  
Mutagenesis of the infectious MMTV provirus, pHYB-MTV, allows localization 
of cis- or trans-acting factors as well as the identification of genes and proteins 
that are necessary for infection and trafficking to the mammary gland in vivo.  To 
determine these requirements, a trimethoprim transposon was inserted randomly 
into pHYB-MTV, and each MMTV mutant was screened for the location of the 
insertion by colony PCR.  Transposon mutants from different genes were selected 
and stably transfected into XC cells since previous results have shown that 
injection of XC cells stably transfected with pHYB-MTV allows productive 
infection of mice (155,253). 
 Expression of the stably transfected transposon mutants was verified by 
RT-PCR and immunoblot analysis before injection into mice.  However, some of 
the transposon mutants did not produce the expected results.  The mutant env 95 
did not express the normal sag transcript, and instead a doublet of ca. 600 bp and 
another band ca. 400 bp was observed.  Although the trimethoprim transposon is 
not located near the splice donor or acceptor for sag, it is possible that the 
insertion disrupted sequences necessary for proper splicing.  Alternatively, a 
splicing enhancer element may have been interrupted or moved farther away to 
prevent interaction with the splice acceptor, or the insertion of the trimethoprim 
transposon might have exposed cryptic splice donor acceptor sites that then are 
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used by the MMTV mutant virus.  Gag protein levels of the mutant env 95, as 
well as mutants env 12 and sag 8, also were considerably lower than wild type 
protein levels.  Although the insertions were not located in the gag gene, it is 
likely that they are interfering in the export of unspliced mRNA, which is required 
for expression of Gag proteins. 
 Stably transfected transposon mutants expressing the expected transcripts 
and proteins were selected from each gene and injected into BALB/c weanling 
mice to determine which mutants allowed infection and trafficking to the 
mammary gland.  An MMTV infection can easily be verified by deletion of Sag-
reactive T cells (140,155); therefore, the injected mice were tested for deletion of 
CD4+Vβ14+ T cells, which react with the Sag expressed by pHYB-MTV.  No 
deletion was observed for any of the stably transfected transposon mutants except 
a mutation in the U3 region of the 5’ LTR, which suggested that each gene was 
necessary for MMTV infection.  This result is not surprising for the gag and pol 
genes since they express proteins essential for particle formation, replication, and 
integration.  Also since the Sag protein interaction with the CD4+Vβ14+ T cells 
causes deletion and the sag mutants lack a functional Sag, the absence of deletion 
for these stably transfected transposon mutants was expected.  However, the env 
mutant injected into the mice not only interrupted the env gene, but also did not 
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allow high Gag expression levels.  Therefore, the lack of deletion observed with 
env mutants could be attributable to a deficiency in Gag or Env protein. 
 To determine if the injected transposon mutants could traffic to mammary 
tissue, mammary gland RNA was harvested and analyzed for gag and sag 
transcripts.  Most of the mutant-injected mice did not produce either mRNA 
product.  However, one injected mouse from each sag mutant expressed a sag 
mRNA product.  Previous experiments have indicated that Sag is necessary for 
viral spread in the mammary gland, and our lab has shown that MMTV mutants 
expressing nonfunctional sag genes were able to sporadically infect mammary 
glands of mice (69,71,90,155,253).  The sag transposon mutants infected 
mammary glands approximately 25% of the time, in agreement with previous 
findings.  The ability of sag mutants to cause sporadic infections may be due to 
recombination between the sag mutants and endogenous MMTVs of BALB/c 
mice.  Therefore, it is possible that recombination was responsible for deletion of 
the trimethoprim transposon to allow functional Sag expression and subsequent 
infection of the mammary gland. 
 
4.2.5 Identification of MMTV sequences necessary for RNA export 
 
 
 Both complex and simple retroviruses require an RNA element in addition 
to either viral and/or host proteins for the export of unspliced or partially spliced 
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RNA to the cytoplasm for the subsequent expression of Gag proteins (45,46,229).  
Previous results indicated that a viral RNA export system might have been 
disrupted during mutagenesis of the MMTV provirus.  RNA export systems are 
usually found in the 3’ end of the virus and insertion of GFP within the 3’ half of 
the MMTV provirus compromised Gag expression.  Subsequently, MMTV 
proviruses containing transposons in the 3’ region were utilized to determine 
specific insertion sites that do not allow Gag expression. 
 All the mutants examined expressed gag mRNA as assessed by RT-PCR 
from total RNA, yet three of the env mutants, env 12, env 148 and env 149, were 
unable to express Gag protein after transient transfections.  The results of 
transient transfections using mutant env 149 did not correspond to the wild-type 
expression levels observed in stable transfections with the same mutant.  It is 
possible that the transposon in the env 149 mutant was inserted adjacent to a 
sequence necessary for RNA export instead of disrupting the sequence.  This 
insertion might cause a reduction in Gag expression that would be more apparent 
in transient transfections where only a fraction of the cells receive the provirus.  
RNA fractionation of cells transfected with each of the three env mutants 
indicated that gag mRNA export was decreased when compared to that of wild-
type proviruses, suggesting that the loss of Gag expression results from decreased 
export of the gag transcript. 
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4.2.6 MMTV lacks detectable CTE activity 
 
 
 Viral export systems are different depending on the complexity of the 
retrovirus (45,46,229).  MMTV is classified as a simple retrovirus, and simple 
retroviruses contain a CTE or CTE-like element, which binds host proteins 
required for export of the unspliced transcripts (46,83,116,165).  Most of these 
RNA elements are less than 200 bp and are located in untranslated regions near 
the 3’ LTR; however, a larger CTE-like element located in the coding region of 
the pol gene has been identified in a murine endogenous retrovirus (251).  MMTV 
does not contain any untranslated regions near the 3’end of the provirus and, 
therefore, a potential CTE must be located in a coding region.  The three env 
mutants are localized within the MMTV env gene, with env 12 and env 148 
located approximately 200 bp apart at the 5’ end of env and env 149 located at the 
3’ end of env directly upstream of the SA for sag near the 3’ LTR (Figs. 3.24 and 
3.37). 
 MMTV fragments from the 3’ end of the provirus were placed in a CTE-
dependent luciferase vector to assay for CTE activity.  The fragments tested 
overlapped (i) all three env mutant sites, (ii) the two 5’ env mutant sites, (iii) the 
one 3’ env mutant site, or (iv) the 3’ MMTV LTR.  Such combinations were used 
to determine if two different elements or a bipartite element were required for 
RNA export.  The CTE-dependent luciferase vectors containing different MMTV 
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fragments were transiently transfected into XC cells, which express MMTV Gag 
proteins and must support unspliced RNA export.  None of the MMTV fragments 
rescued luciferase expression as compared to the levels of the intronless-luciferase 
vector, which expresses luciferase approximately 100-fold less than the intron-
containing vector.  However, the positive control CTE from MPMV, which 
should elevate luciferase expression in intronless vectors, increased luciferase 
levels less than 2-fold in these rat cells.  Higher efficiency of the MPMV CTE has 
been observed in human cell lines (256).  Therefore, MMTV fragments were 
tested for CTE activity in the human 293T cell line, which allows MMTV protein 
expression.  The MPMV CTE increased luciferase levels 4-fold in 293T cells, 
which is comparable to the levels reported with other CTE-dependent reporter 
vectors.  However, under these conditions, the MMTV fragments did not increase 
luciferase levels of the intronless vector, suggesting that MMTV lacks a CTE. 
 
4.2.7 Identification of an MMTV trans-acting factor for viral RNA export 
 
 
 Complex retroviruses express trans-acting proteins that bind to an RNA 
element on unspliced or partially spliced transcripts for cytoplasmic export.  For 
HIV-1 and HTLV-1, these proteins are Rev and Rex, which bind to the RRE and 
the RxRE, respectively (3,84,88,174).  A similar protein Rec and its binding site, 
the RcRE, has been identified in the betaretrovirus HERV-K to allow export of 
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incompletely spliced mRNAs to the cytoplasm (17,18,131,133,134).  HERV-K 
has considerable homology to MMTV (131), suggesting that MMTV might also 
encode a trans-acting protein for unspliced RNA export. 
 Each of the identified viral export proteins are expressed from a doubly 
spliced transcript and, therefore, attempts were made to identify such an RNA 
from MMTV and TBLV-infected cells.  TBLV is 98% identical to MMTV but 
contains a deletion of the negative regulatory elements in the U3 region of the 
LTR to allow higher expression in T cells (10,32,50).  These related viruses 
should encode the same system for export of unspliced transcripts to the 
cytoplasm.  Novel mRNAs were detected from both XC cells stably transfected 
with pHYB-MTV as well as Jurkat cells stably transfected with pTBLV.  
Sequence analysis of these novel mRNAs from each cell line indicated they were 
identical doubly spliced products using the known splice donors and splice 
acceptors found in viral RNA.  The product of this novel RNA was named Rem. 
 The predicted protein sequence of the novel rem mRNA contained the Env 
leader peptide, 162 amino acids from gp52 (SU), and 41 amino acids from gp36 
(TM).  This sequence differs from the other Rev-related proteins since Rem 
contains the entire leader peptide, including the signal peptidase cleavage site, 
whereas the Rev-related proteins lack the cleavage site of the leader peptide due 
to RNA splicing.  Rem contains an NLS and NES for possible functions in import 
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and export in addition to an arginine-rich motif, which is likely to function in 
RNA binding.  Each of these putative domains closely resembles the recognized 
domains of Rev and the Rev-related proteins, suggesting that MMTV encodes a 
trans-acting protein, Rem, required for unspliced mRNA export to the cytoplasm.  
However, the domains important for RNA export are all located in the MMTV 
leader peptide, which usually is cleaved off after insertion of the nascent 
polypeptide into the ER membrane.  If Rem is an MMTV trans-acting factor for 
unspliced RNA export, it will be important to determine the process by which this 
protein escapes recognition by the signal recognition particle (25,112). 
 Trans-acting proteins can be identified through complementation analyses 
(141,216); therefore, a complementation experiment was performed using the two 
env mutants in the rem mRNA open reading frame to determine if MMTV 
encodes a trans-acting protein.  The addition of wild-type MMTV to XC cells 
stably transfected with the mutant env 148 rescued the export of unspliced 
transcripts.  Moreover, our laboratory recently showed that overexpression of the 
Rem or Rem-GFP cDNAs in XC cells can increase export of mutant 148 
unspliced RNA to the cytoplasm from 7 to 15-fold (J. Mertz, personal 
communication).  These results further indicate that MMTV expresses a trans-
acting protein, Rem, which functions in export of unspliced mRNA. 
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 Although Rem and the other retroviral proteins involved in RNA export 
contain similar domains, sequence comparisons showed no significant homology.  
This is most likely due to the organization of the proteins, which indicates the 
domains are located in different positions throughout each protein (Fig. 4.1).  
Rem also is ca. three times larger than the other RNA export proteins, yet the 
domains involved in RNA export are located only in the N-terminus, or leader 
peptide.  The function of the Rem C-terminus is not presently understood since 
the other proteins do not contain such a large sequence without any known 
domains.  It is possible that the C-terminus is required for Rem to fold properly 
and expose the RNA export domains.  However, proper folding can only occur 
once the protein escapes recognition by the signal recognition particle.  
Alternatively, Rem may be cleaved at the leader peptide to form two functional 
proteins, one that functions in RNA export and an additional MMTV accessory 



















Fig. 4.1. Domain organization of trans-acting factors used in RNA transport. 
HIV-1 Rev, HTLV-1 Rex, HERV-K Rec, and MMTV Rem are all 
trans-acting factors identified in viral RNA export.  Each protein 
contains an NLS/RNA-binding domain near the N-terminus which 
functions in nuclear import and binding of the protein to RNA 
elements on incompletely spliced mRNAs.  An NES/Activation 
domain is located towards the C-terminus, except in Rem, and 
functions in exporting the protein/RNA complex to the cytoplasm.  





 Trans-acting proteins involved in RNA export require an RNA element on 
the unspliced RNA for binding and mRNA export.  Such an element would not be 
identified by complementation analysis.  However, previous results have shown 
that a derivative of the MMTV hybrid provirus (MMTV-neo) was able to be 
complemented for viral infectivity with wild type MMTV.  This MMTV 
derivative contains only the 3’ end of the env sequence, starting approximately 40 
bp upstream of the 3’LTR, and the 3’ LTR(205).  The location of RNA elements 
for HIV-1, HTLV-1, and HERV-K all are in different regions of these 
retroviruses.  The HIV-1 RRE is present only in unspliced or partially spliced 
mRNAs, specifically in the intron of the env sequence, whereas the HTLV-1 
RxRE and the HERV-K RcRE are both located in all mRNAs, specifically in the 
U3R region of the 3’ LTR (88,132).  From the MMTV derivative data, it seems 
likely that the MMTV RNA element maps to the 3’ LTR, similar to HTLV-1 and 
HERV-K.  The sequence from the MMTV hybrid provirus derivative, other 
transposon mutants in the 3’ LTR, and complementation assays between Rem 
cDNA and various reporter gene constructs should allow localization of the Rem-








4.2.8 MMTV is a complex retrovirus  
 
 
 Retroviruses are divided into two categories based on their genome 
organization, which are (i) simple retroviruses and (ii) complex retroviruses, and 
both contain coding regions for proteins expressed from gag, pro, pol, and env.  
However, complex retroviruses contain multiply spliced mRNAs that express 
several accessory proteins, which affect viral RNA synthesis or processing, 
whereas simple retroviruses contain at most one additional coding region that is 
not involved in RNA synthesis or processing and is only singly spliced (40). 
 MMTV is presently classified as a simple retrovirus since it was only 
known to encode one additional protein, Sag, which is important for MMTV 
infection and tumorigenesis (191).  However, we have now identified a novel, 
multiply spliced mRNA, rem, from MMTV-infected cells, and the Rem predicted 
protein sequence contains domains similar to RNA export proteins expressed 
from complex retroviruses (Fig. 4.1).  Additionally, MMTV mutants unable to 
export unspliced mRNA were complemented with both wild-type MMTV and a 
Rem cDNA plasmid, indicating that MMTV expresses a trans-acting protein, 
Rem, which can overcome an RNA export defect.  Since MMTV currently (i) 
produces a multiply spliced mRNA, (ii) encodes at least two accessory proteins, 
and (iii) expresses a protein involved in RNA export, it should no longer be 
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classified as a simple retrovirus and, therefore, MMTV should be reclassified as a 
complex retrovirus. 
 
4.3 FUTURE DIRECTIONS 
 
 
 MMTV appears to encode a trans-acting protein responsible for the export 
of unspliced mRNA to the cytoplasm, similar to the complex retroviruses HIV-1 
and HTLV-1 as well as HERV-K.  Much work remains, however, to identify Rem 
as the protein containing this function.  Mutational analysis of the possible NLS 
and NES from Rem will help determine the import and export capabilities of 
Rem.  Rev and the Rev-like proteins all utilize the Crm1 transport system; 
therefore it will be important to determine whether MMTV also uses this system 
or a different RNA or protein transport system.  The elucidation of the RNA 
element utilized by MMTV for export of unspliced transcripts also will help 
determine important sequences necessary for binding of the Rem protein.  These 
studies will not only allow a better understanding of the replicative ability of 
MMTV but also will provide locations of both cis- and trans-acting factors 




List of abbreviations used: 
 
Ab  antibody 
ALV  avian leukemia retrovirus 
ARE  adenosine/uridine-rich element 
ASV  avian sarcoma retrovirus 
BGH  bovine growth hormone 
BHI  brain-heart infusion 
bp  base pairs 
C-terminus carboxy-terminus 
CaCl2  calcium chloride 
ca.  approximately 
CA  capsid protein 
CBC  cap-binding complex 
CCD  cytochalasin D 
CDP  CCAAT displacement protein 
CFU  colony-forming units 
Crm1  chromosome region maintenance 1 
CTE  constitutive transport element 
DAP  diaminopimelic acid   
DEPC  diethyl pyrocarbonate 
Dex  dexamethasone 
DHFR  dihydrofolate reductase 
DHFR-1 trimethoprim 
DMEM Dulbecco’s modified Eagle’s medium  
DTT  dithiothreitol 
E. coli  Escherichia coli 
EDTA  ethylenediaminetetraacetate 
EGTA  ethyleneglycol-bis N,N’-tetra acetic acid 
Env  envelope protein 
ER  endoplasmic reticulum 
FACS  fluorescence-activated cell sorting 
FCS  fetal calf serum 
FG  phenylalanine-glycine repeats 
GALT  gut-associated lymphoid tissue 
GFP  green fluorescent protein 
HERV-K human endogenous retrovirus type K 
HIV-1  human immunodeficiency virus type 1 
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hnRNP heterogeneous nuclear ribonucleoparticle 
HRE  hormone response element 
HTLV-1 human T-cell leukemia virus type 1 
IAP  intracisternal-A particle 
IN  integrase protein 
kb  kilobases 
lacI  lac repressor gene 
LB  Luria Broth 
LSB  low-salt buffer 
LTR  long terminal repeat 
M cells membranous epithelial cells 
MA  matrix protein 
MgCl2   magnesium chloride 
MEM  Minimum Essential Medium 
MHC  major histocompatibility complex 
MHR  major homology region 
MLV  murine leukemia virus 
MMTV Mouse mammary tumor virus 
MPMV Mason-Pfizer Monkey virus 
mTfR1  mouse transferrin receptor 1 
MYM  multiple Yop mutant    
N-terminus amino-terminus 
NaCl  sodium chloride 
NaOAc sodium acetate 
NaOH  sodium hydroxide 
NC  nucleocapsid protein 
NES  nuclear export signal  
NLS  nuclear localization signal 
NPC  nuclear pore complex 
NRE  negative regulatory elements 
NTF2  nuclear transport factor 2 
ONPF  o-Nitrophenyl-b-D-fucoside 
ORF  open reading frame 
PAGE  polyacrylamide gel electrophoresis 
PB  primer binding site 
PBS  phosphate-buffered saline 
PCR  polymerase chain reaction  
PMN  polymorphonuclear leukocyte 
PMSF  phenylmethylsulfonyl fluoride 
PPT  polypurine tract 
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PR   protease protein 
RBD  RNA-binding domain 
RcRE  Rec-response element 
RIPA  radioimmunoprecipitation assay 
Rluc  Renilla luciferase 
RNP  ribonucleoparticle 
RRE  Rev-response element 
RT  reverse transcriptase protein  
RT-PCR Reverse-transcriptase PCR 
RxRE  Rex-response element 
SA  splice acceptor 
Sag  Superantigen protein 
SATB1 special AT-rich sequence binding protein 1 
SD  Splice donor 
SDS  sodium dodecyl sulfate 
SRV  simian retrovirus 
SU  surface protein 
TAP  Tip-associated protein 
TBLV  Type B leukemogenic virus 
TBST  Tris-Buffered Saline Tween-20 
TCR  T-cell receptor 
TM  transmembrane protein 
TTSS  type III secretion system 
Vβ  β-subunit variable chain 
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